

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 June 2004 (24.06.2004)

PCT

(10) International Publication Number
WO 2004/052309 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2003/039492
- (22) International Filing Date:
11 December 2003 (11.12.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10/317,391 11 December 2002 (11.12.2002) US
- (71) Applicant (*for all designated States except US*): **ISIS PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **SHANAHAN, William, R.** [US/US]; 15 Ellicott Way, Sugar Land, TX 77479 (US). **FREIER, Susan, M.** [US/US]; 2946 Renault Street, San Diego, CA 92122 (US). **DOBIE, Kenneth, W.** [GB/US]; 703 Stratford Court, #4, Delmar, CA 92014 (US).
- (74) Agent: **LEGAARD, Paul, K.**; Cozen O'Connor, 1900 Market Street, Philadelphia, PA 19103 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: MODULATION OF STAT 6 EXPRESSION

(57) Abstract: Compounds, compositions and methods are provided for modulating the expression of STAT 6. The compositions comprise oligonucleotides, targeted to nucleic acid encoding STAT 6. Methods of using these compounds for modulation of STAT 6 expression and for diagnosis and treatment of disease associated with expression of STAT 6 are provided.

WO 2004/052309 A2

MODULATION OF STAT 6 EXPRESSION

FIELD OF THE INVENTION

5 The present invention provides compositions and methods for modulating the expression of STAT 6. In particular, this invention relates to compounds, particularly oligomeric compounds such as oligonucleotide compounds, which, in some embodiments, hybridize with nucleic acid molecules encoding STAT 6. Such compounds are shown herein to modulate the expression of STAT 6.

BACKGROUND OF THE INVENTION

0 Cytokines function as protein mediators that play a critical role in host defense and serve as a communication link between cells of native and acquired immunity. Cells respond to cytokines with specific biological changes that are dependent on the activation of new gene expression.

5 Studies of the mechanism by which signals are mediated from the receptor to the nucleus by the interferon cytokines have revealed the activation of latent cytoplasmic transcription factors that subsequently translocate to the nucleus (Bromberg, BioEssays, 2001, 23, 161-169).

0 The proteins of the STAT family (signal transducers and activators of transcription) are latent transcription factors that are abundantly expressed in many cell types. STATs are activated by phosphorylation on a single tyrosine in response to extracellular ligands. An active STAT dimer is formed through reciprocal interactions between the SH2 domain of one monomer and the phosphorylated tyrosine of the other monomer. The dimers accumulate in the nucleus, recognize specific DNA elements in the promoters of genes and activate transcription so that growth control and survival of normal cells in a developing or adult mammal are carefully balanced. Many of the signals that influence this balance are delivered by circulating polypeptides, whose binding to cell surface receptors governs gene-specific transcription. It has been shown that human cancer cells have lost control of these signaling mechanisms. In addition to persistent unregulated mitogenic signaling, the lack of suppressive signals is also critical in the development of cancers (Bromberg, BioEssays, 2001, 23, 161-169).

STAT 6 (also known as interleukin 4-STAT) was cloned and mapped to chromosome 12q13 (Leek et al., Cytogenet. Cell Genet., 1997, 79, 208-209; Quelle et al., Mol. Cell Biol.,

-2-

1995, 15, 3336-3343). Nucleic acid sequences encoding STAT 6 are disclosed and claimed in US patent 5,710,266 (McKnight and Hou, 1998).

STAT 6 is primarily expressed as a 4 kb transcript in hematopoietic cells and expressed variably in other tissues (Quelle et al., Mol. Cell Biol., 1995, 15, 3336-3343). A unique truncated isoform of STAT 6 is expressed in mast cells (Sherman, Immunol. Rev., 2001, 179, 48-56). Disclosed and claimed in PCT publication WO 99/10493 are nucleic acid sequences encoding variants of STAT 6 known as STAT 6b and STAT 6c as well as vectors comprising said nucleic acid sequences (Patel et al., 1999).

STAT 6 is an integral transcription factor involved in interleukin 4 and interleukin 13 signaling. Following activation of their respective receptors, interleukin 4 and interleukin 13 cause their common interleukin 4 receptor alpha chain to become phosphorylated by JAK3 and to subsequently bind to STAT 6. STAT 6 is then phosphorylated by JAK1, homodimerizes and translocates to the nucleus where it binds interleukin 4 response elements and initiates the transcription of a number of genes including IgE (Danahay et al., Inflamm. Res., 2000, 49, 692-699).

STAT 6 is involved in key pathological mechanisms in rheumatoid arthritis which operate in early and late stages of the disease (Muller-Ladner et al., J. Immunol., 2000, 164, 3894-3901).

Ghilardi et al. have found that STAT 6 interacts with an isoform of the leptin receptor (OB-R) and is thus, a potential mediator of the anti-obesity effects of leptin (Ghilardi et al., Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 6231-6235).

STAT 6 knockout mice are viable and develop normally with the exception that interleukin 4 functions are eliminated (Ihle, Curr. Opin. Cell Biol., 2001, 13, 211-217). Additionally, STAT 6 knockout mice fail to develop antigen-induced airway hyper-reactivity in a model of airway inflammation (Kuperman et al., J. Exp. Med., 1998, 187, 939-948). Inhibition of STAT 6 is expected to attenuate the allergic response and thus, represents an attractive target for drug discovery strategies (Hill et al., Am. J. Respir. Cell Mol. Biol., 1999, 21, 728-737).

Small molecule inhibitors of STAT 6 are disclosed and claimed in PCT publication WO 00/27802 and Japanese Patent JP 2000229959 (Eyermann et al., 2000; Inoue et al., PCT, 2000, Abstract only). Disclosed and claimed in US Patent 6,207,391 are methods for screening modulators of STAT 6 binding to a STAT 6 receptor (Wu and McKinney, 2001).

-3-

Wang et al. have demonstrated targeted disruption of STAT 6 DNA-binding activity by a phosphorothioate cis-element decoy oligonucleotide (Wang et al., Blood, 2000, 95, 1249-1257).

Hill et al. have used a series of homologous human and murine antisense oligonucleotides targeting STAT 6 to interrupt interleukin 4 and interleukin 13 signaling and attenuate germline C-epsilon transcription in vitro (Hill et al., Am. J. Respir. Cell Mol. Biol., 1999, 21, 728-737). Subsequently, the in vitro and in vivo pharmacology of three of the antisense oligonucleotides used in the latter study was investigated. Although the oligonucleotides downregulated STAT 6 mRNA, their action was not sufficient to influence alterations in mRNA levels (Danahay et al., Inflamm. Res., 2000, 49, 692-699).

Currently, there are no known therapeutic agents that effectively inhibit the synthesis of STAT 6. Consequently, there remains a long felt need for additional agents capable of effectively inhibiting STAT 6 function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of STAT 6 expression.

The present invention provides compositions and methods for modulating STAT 6 expression.

SUMMARY OF THE INVENTION

The present invention is directed to compounds, especially nucleic acid and nucleic acid-like oligomers, which are targeted to a nucleic acid encoding STAT 6, and which modulate the expression of STAT 6. Pharmaceutical and other compositions comprising the compounds of the invention are also provided. Further provided are methods of screening for modulators of STAT 6 and methods of modulating the expression of STAT 6 in cells, tissues or animals comprising contacting said cells, tissues or animals with one or more of the compounds or compositions of the invention. Methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of STAT 6 are also set forth herein. Such methods comprise administering a therapeutically or prophylactically effective amount of one or more of the compounds or compositions of the invention to the person in need of treatment.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs compounds, including oligomers such as oligonucleotides and similar species for use in modulating the function or effect of nucleic acid molecules encoding STAT 6. This is accomplished by providing oligonucleotides that specifically hybridize with one or more nucleic acid molecules encoding STAT 6. As used herein, the terms "target nucleic acid" and "nucleic acid molecule encoding STAT 6" have been used for convenience to encompass DNA encoding STAT 6, RNA (including pre-mRNA and mRNA or portions thereof) transcribed from such DNA, and also cDNA derived from such RNA. The hybridization of a compound of this invention with its target nucleic acid is generally referred to as "antisense." Consequently, a mechanism believed to be included in the practice of some embodiments of the invention is referred to herein as "antisense inhibition." Such antisense inhibition is typically based upon hydrogen bonding-based hybridization of oligonucleotide strands or segments such that at least one strand or segment is cleaved, degraded, or otherwise rendered inoperable. In this regard, specific nucleic acid molecules and their functions can be targeted for such antisense inhibition.

The functions of DNA to be interfered with include, but are not limited to, replication and transcription. Replication and transcription, for example, can be from an endogenous cellular template, a vector, a plasmid construct or otherwise. Functions of RNA to be interfered with also include functions such as, for example, translocation of the RNA to a site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more RNA species, and catalytic activity or complex formation involving the RNA which may be engaged in or facilitated by the RNA. One result of such interference with target nucleic acid function is modulation of the expression of STAT 6. In the context of the present invention, "modulation" and "modulation of expression" mean either an increase (stimulation) or a decrease (inhibition) in the amount or levels of a nucleic acid molecule encoding the gene, e.g., DNA or RNA. Inhibition is often a desired form of modulation of expression and mRNA is often a desired target nucleic acid.

In the context of this invention, "hybridization" means the pairing of complementary strands of oligomeric compounds. In the present invention, one mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleobases) of the strands of oligomeric compounds. For example, adenine and thymine are complementary nucleobases that

pair through the formation of hydrogen bonds. Hybridization can occur under varying circumstances.

The compounds of the invention are specifically hybridizable when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity. In some embodiments, there may be a sufficient degree of complementarity to avoid non-specific binding of the compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of *in vivo* assays or therapeutic treatment, and under conditions in which assays are performed in the case of *in vitro* assays.

In the present invention the phrase “stringent hybridization conditions” or “stringent conditions” refers to conditions under which a compound of the invention will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances and in the context of this invention, “stringent conditions” under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they are being investigated.

“Complementary,” as used herein, refers to the capacity for precise pairing between two nucleobases of an oligomeric compound. For example, if a nucleobase at a certain position of an oligonucleotide (an oligomeric compound), is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, the target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position. The oligonucleotide and the further DNA, RNA, or oligonucleotide molecule are complementary to each other when a sufficient number of complementary positions in each molecule are occupied by nucleobases which can hydrogen bond with each other. Thus, “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleobases such that stable and specific binding occurs between the oligonucleotide and a target nucleic acid.

It is understood in the art that the sequence of a compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. Moreover, an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or hairpin structure). The compounds of the present invention can comprise at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence complementarity to a target

region within the target nucleic acid sequence to which they are targeted. For example, a compound in which 18 of 20 nucleobases of the compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, a compound which is 18 nucleobases in length having 4 (four) noncomplementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would fall within the scope of the present invention. Percent complementarity of a compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., J. Mol. Biol., 1990, 215, 403-410; and Zhang and Madden, Genome Res., 1997, 7, 649-656).

Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison WI), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489). In some embodiments, homology, sequence identity or complementarity, between the oligomeric compound and target is between about 50% to about 60%, between about 60% to about 70%, between about 70% and about 80%, or between about 80% and about 90%. In other embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%.

According to the present invention, compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds that hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges or loops. Once introduced to a system, the compounds of the invention may elicit the action of one or more enzymes or structural proteins to effect modification of the target nucleic acid.

One non-limiting example of such an enzyme is RNase H, a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are "DNA-like" elicit RNase H. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of

oligonucleotide-mediated inhibition of gene expression. Similar roles have been postulated for other ribonucleases such as those in the RNase III and ribonuclease L family of enzymes.

While one form of an antisense compound is a single-stranded antisense oligonucleotide, in many species the introduction of double-stranded structures, such as double-stranded RNA (dsRNA) molecules, has been shown to induce potent and specific antisense-mediated reduction of the function of a gene or its associated gene products. This phenomenon occurs in both plants and animals and is believed to have an evolutionary connection to viral defense and transposon silencing.

The first evidence that dsRNA could lead to gene silencing in animals came in 1995 from work in the nematode, *Caenorhabditis elegans* (Guo and Kempheus, Cell, 1995, 81, 611-620). Montgomery et al. have shown that the primary interference effects of dsRNA are posttranscriptional (Montgomery et al., Proc. Natl. Acad. Sci. USA, 1998, 95, 15502-15507). The posttranscriptional antisense mechanism defined in *Caenorhabditis elegans* resulting from exposure to double-stranded RNA (dsRNA) has since been designated RNA interference (RNAi). This term has been generalized to mean antisense-mediated gene silencing involving the introduction of dsRNA leading to the sequence-specific reduction of endogenous targeted mRNA levels (Fire et al., Nature, 1998, 391, 806-811). Recently, it has been shown that it is, in fact, the single-stranded RNA oligomers of antisense polarity of the dsRNAs which are the potent inducers of RNAi (Tijsterman et al., Science, 2002, 295, 694-697).

The oligonucleotides of the present invention also include variants in which a different base is present at one or more of the nucleotide positions in the oligonucleotide. For example, if the first nucleotide is an adenosine, variants may be produced which contain thymidine, guanosine or cytidine at this position. This may be done at any of the positions of the oligonucleotide. These oligonucleotides are then tested using the methods described herein to determine their ability to inhibit expression of STAT 6 mRNA.

In the context of this invention, the term "oligomeric compound" refers to a polymer or oligomer comprising a plurality of monomeric units. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics, chimeras, analogs and homologs thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions that function similarly. Such modified or substituted oligonucleotides are often favorable over native forms because of desirable properties such as, for example, enhanced

cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.

While oligonucleotides are one form of the compounds of this invention, the present invention comprehends other families of compounds as well, including but not limited to

5 oligonucleotide analogs and mimetics such as those described herein.

The compounds in accordance with this invention can comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). One of ordinary skill in the art will appreciate that the invention embodies compounds of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 0 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 nucleobases in length.

In one embodiment, the compounds of the invention are 12 to 50 nucleobases in length. One having ordinary skill in the art will appreciate that this embodies compounds of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 5 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleobases in length.

In another embodiment, the compounds of the invention are 15 to 30 nucleobases in length. One having ordinary skill in the art will appreciate that this embodies compounds of 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length.

In other embodiments, the compounds are oligonucleotides from about 12 to about 50) nucleobases or from about 15 to about 30 nucleobases.

Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative compounds are considered to be suitable compounds as well.

Exemplary compounds include oligonucleotide sequences that comprise at least the 8 ; consecutive nucleobases from the 5'-terminus of one of the illustrative compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately upstream of the 5'-terminus of the compound that is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80 nucleobases). Similarly, compounds are represented by oligonucleotide sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative compounds (the remaining nucleobases being a consecutive stretch of the same oligonucleotide beginning immediately downstream of the 3'-terminus of the compound that is specifically hybridizable to the target nucleic acid and continuing until the oligonucleotide contains about 8 to about 80

nucleobases). One having skill in the art armed with the compounds illustrated herein will be able, without undue experimentation, to identify additional compounds.

“Targeting” a compound to a particular nucleic acid molecule, in the context of this invention, can be a multistep process. The process can begin with the identification of a target nucleic acid whose function is to be modulated. This target nucleic acid may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target nucleic acid molecule encodes STAT 6.

The targeting process can also include determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result. Within the context of the present invention, the term “region” is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic. Within regions of target nucleic acids are segments. “Segments” are defined as smaller or sub-portions of regions within a target nucleic acid. “Sites,” as used in the present invention, are defined as positions within a target nucleic acid.

Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the “AUG codon,” the “start codon” or the “AUG start codon.” A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms “translation initiation codon” and “start codon” can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, “start codon” and “translation initiation codon” refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA transcribed from a gene encoding STAT 6, regardless of the sequence(s) of such codons. It is also known in the art that a translation termination codon (or “stop codon”) of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively).

The terms “start codon region” and “translation initiation codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous

-10-

nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon. Consequently, the "start codon region" (or "translation initiation codon region") and the "stop codon region" (or "translation termination codon region") are all regions which may be targeted effectively with the compounds of the present invention.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Within the context of the present invention, a suitable region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.

Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene), and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene). The 5' cap site of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site. The 5' cap region can be targeted.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. Targeting splice sites, i.e., intron-exon junctions or exon-intron junctions, may also be particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also suitable target sites. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts." It is also known that introns can be effectively targeted using antisense compounds targeted to, for example, DNA or pre-mRNA.

It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants."

-11-

More specifically, “pre-mRNA variants” are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and exonic sequence.

Upon excision of one or more exon or intron regions, or portions thereof during splicing, pre-mRNA variants produce smaller “mRNA variants.” Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as “alternative splice variants.” If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as “alternative start variants” of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon are known as “alternative stop variants” of that pre-mRNA or mRNA. One specific type of alternative stop variant is the “polyA variant” in which the multiple transcripts produced result from the alternative selection of one of the “polyA stop signals” by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites. Within the context of the invention, the types of variants described herein are also suitable target nucleic acids.

Locations on the target nucleic acid to which the compounds hybridize are hereinbelow referred to as “suitable target segments.” As used herein, the term “suitable target segment” is defined as at least an 8-nucleobase portion of a target region to which an active compound is targeted. While not wishing to be bound by theory, it is presently believed that these target segments represent portions of the target nucleic acid which are accessible for hybridization.

While the specific sequences of particular suitable target segments are set forth herein, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional suitable target segments may be identified by one having ordinary skill.

Once one or more suitable target regions, segments or sites have been identified, compounds are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

The oligomeric compounds are also targeted to or not targeted to regions of the target nucleobase sequence (e.g., such as those disclosed in Example 13) comprising nucleobases 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550,

551-600, 601-650, 651-700, 701-750, 751-800, 801-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500, 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, 2001-2050, 2051-2100, 2101-2150, 2151-2200, 2201-2250, 2251-2300, 2301-2350, 2351-2400, 2401-2450, 2451-2500, 2501-2550, 2551-2600, 2601-2650, 2651-2700, 2701-2750, 2751-2800, 2801-2850, 2851-2900, 2901-2950, 2951-3000, 3001-3050, 3051-3100, 3101-3150, 3151-3200, 3201-3250, 3251-3300, 3301-3350, 3351-3400, 3401-3450, 3451-3500, 3501-3550, 3551-3600, 3601-3650, 3751-3700, 3701-3750, 3751-3800, 3801-3850, 3851-3900, 3901-3950, 3951-4000, 4001-4050, 4051-4100, 4101-4150, 4151-4200, 4201-4250, 4251-4300, 4301-4350, 4351-4400, 4401-4450, 4451-4500, 4501-4550, 4551-4600, 4601-4650, 4751-4700, 4701-4750, 4751-4800, 4801-4850, 4851-4900, 4901-4950, 4951-5000, 5001-5050, 5051-5100, 5101-5150, 5151-5200, 5201-5250, 5251-5300, 5301-5350, 5351-5400, 5401-5450, 5451-5500, 5501-5550, 5551-5600, 5601-5650, 5751-5700, 5701-5750, 5751-5800, 5801-5850, 5851-5900, 5901-5950, 5951-6000, 6001-6050, 6051-6100, 6101-6150, 6151-6200, 6201-6250, 6251-6300, 6301-6350, 6351-6400, 6401-6450, 6451-6500, 6501-6550, 6551-6600, 6601-6650, 6651-6700, 6701-6750, 6751-6800, 6801-6850, 6851-6900, 6901-6950, 6951-7000, 7001-7050, 7051-7100, 7101-7150, 7151-7200, 7201-7250, 7251-7300, 7301-7350, 7351-7400, 7401-7450, 7451-7500, 7501-7550, 7551-7600, 7601-7650, 7651-7700, 7701-7750, 7751-7800, 7801-7850, 7851-7900, 7901-7950, 7951-8000, 8001-8050, 8051-8100, 8101-8150, 8151-8200, 8201-8250, 8251-8300, 8301-8350, 8351-8400, 8401-8450, 8451-8500, 8501-8550, 8551-8600, 8601-8650, 8651-8700, 8701-8750, 8751-8800, 8801-8850, 8851-8900, 8901-8950, 8951-9000, 9001-9050, 9051-9100, 9101-9150, 9151-9200, 9201-9250, 9251-9300, 9301-9350, 9351-9400, 9401-9450, 9451-9500, 9501-9550, 9551-9600, 9601-9650, 9651-9700, 9701-9750, 9751-9800, 9801-9850, 9851-9900, 9901-9950, 9951-10000, 10001-10050, 10051-10100, 10101-10150, 10151-10200, 10201-10250, 10251-10300, 10301-10350, 10351-10400, 10401-10450, 10451-10500, 10501-10550, 10551-10600, 10601-10650, 10651-10700, 10701-10750, 10751-10800, 10801-10850, 10851-10900, 10901-10950, 10951-11000, 11001-11050, 11051-11100, 11101-11150, 11151-11200, 11201-11250, 11251-11300, 11301-11350, 11351-11400, 11401-11450, 11451-11500, 11501-11550, 11551-11600, 11601-11650, 11651-11700, 11701-11750, 11751-11800, 11801-11850, 11851-11900, 11901-11950, 11951-12000, 12001-12050, 12051-12100, 12101-12150, 12151-12200, 12201-12250, 12251-12300, 12301-12350, 12351-12400, 12401-12450, 12451-12500, 12501-12550, 12551-12600, 12601-12650, 12651-12700, 12701-12750, 12751-12800, 12801-12850, 12851-12900, 12901-12950, 12951-13000, 13001-13050, 13051-13100, 13101-13150, 13151-13200, 13201-13250, 13251-13300, 13301-13350, 13351-13400, 13401-

13450, 13451-13500, 13501-13550, 13551-13600, 13601-13650, 13651-13700, 13701-13750, 13751-13800, 13801-13850, 13851-13900, 13901-13950, 13951-14000, 14001-14050, 14051-14100, 14101-14150, 14151-14200, 14201-14250, 14251-14300, 14301-14350, 14351-14400, 14401-14450, 14451-14500, 14501-14550, 14551-14600, 14601-14650, 14651-14700, 14701-14750, 14751-14800, 14801-14850, 14851-14900, 14901-14950, 14951-15000, 15001-15050, 15051-15100, 15101-15150, 15151-15200, 15201-15250, 15251-15300, 15301-15350, 15351-15400, 15401-15450, 15451-15500, 15501-15550, 15551-15600, 15601-15650, 15651-15700, 15701-15750, 15751-15800, 15801-15850, 15851-15900, 15901-15950, 15951-16000, 16001-16050, 16051-16100, 16101-16150, 16151-16200, 16201-16250, 16251-16300, 16301-16350, 16351-16400, 16401-16450, or 16451-16500, or any combination thereof.

In a further embodiment, the "suitable target segments" identified herein may be employed in a screen for additional compounds that modulate the expression of STAT 6. "Modulators" are those compounds that decrease or increase the expression of a nucleic acid molecule encoding STAT 6 and which comprise at least an 8-nucleobase portion which is complementary to a suitable target segment. The screening method can comprise, for example, the steps of contacting a target segment of a nucleic acid molecule encoding STAT 6 with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding STAT 6. Once it is shown that the candidate modulator or modulators are capable of modulating (e.g. either decreasing or increasing) the expression of a nucleic acid molecule encoding STAT 6, the modulator may then be employed in further investigative studies of the function of STAT 6, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention.

The suitable target segments of the present invention may be also be combined with their respective complementary compounds of the present invention to form stabilized double-stranded (duplexed) oligonucleotides. Such double stranded oligonucleotide moieties have been shown in the art to modulate target expression and regulate translation as well as RNA processing via an antisense mechanism. Moreover, the double-stranded moieties may be subject to chemical modifications (Fire et al., *Nature*, 1998, 391, 806-811; Timmons and Fire, *Nature* 1998, 395, 854; Timmons et al., *Gene*, 2001, 263, 103-112; Tabara et al., *Science*, 1998, 282, 430-431; Montgomery et al., *Proc. Natl. Acad. Sci. USA*, 1998, 95, 15502-15507; Tuschl et al., *Genes Dev.*, 1999, 13, 3191-3197; Elbashir et al., *Nature*, 2001, 411, 494-498; and Elbashir et al., *Genes Dev.* 2001, 15, 188-200). For example, such double-stranded moieties have been shown to inhibit the target by the classical hybridization of antisense strand of the duplex to the

target, thereby triggering enzymatic degradation of the target (Tijsterman et al., Science, 2002, 295, 694-697).

The compounds of the present invention can also be applied in the areas of drug discovery and target validation. The present invention comprehends the use of the compounds and suitable target segments identified herein in drug discovery efforts to elucidate relationships that exist between STAT 6 and a disease state, phenotype, or condition. These methods include, for example, detecting or modulating STAT 6 comprising contacting a sample, tissue, cell, or organism with the compounds of the present invention, measuring the nucleic acid or protein level of STAT 6 and/or a related phenotypic or chemical endpoint at some time after treatment, and optionally comparing the measured value to a non-treated sample or sample treated with a further compound of the invention. These methods can also be performed in parallel or in combination with other experiments to determine the function of unknown genes for the process of target validation or to determine the validity of a particular gene product as a target for treatment or prevention of a particular disease, condition, or phenotype.

The compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. Furthermore, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.

For use in kits and diagnostics, the compounds of the present invention, either alone or in combination with other compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

As one nonlimiting example, expression patterns within cells or tissues treated with one or more compounds are compared to control cells or tissues not treated with compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds that affect expression patterns.

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, FEBS Lett., 2000, 480, 17-24; Celis, et al., FEBS Lett., 2000, 480, 2-16), SAGE (serial analysis of gene expression)(Madden, et al., Drug Discov. Today, 2000, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and

Weissman, *Methods Enzymol.*, 1999, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, 2000, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; Jungblut, et al., *Electrophoresis*, 1999, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, 2000, 480, 2-16; 5 Larsson, et al., *J. Biotechnol.*, 2000, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, 2000, 286, 91-98; Larson, et al., *Cytometry*, 2000, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, 2000, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, 1998, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, 10 *Eur. J. Cancer*, 1999, 35, 1895-904) and mass spectrometry methods (To, *Comb. Chem. High Throughput Screen*, 2000, 3, 235-41).

The compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding STAT 6. For example, oligonucleotides that are shown to hybridize with such efficiency and under such conditions as disclosed herein as to be 5 effective STAT 6 inhibitors will also be effective primers or probes under conditions favoring gene amplification or detection, respectively. These primers and probes are useful in methods requiring the specific detection of nucleic acid molecules encoding STAT 6 and in the amplification of said nucleic acid molecules for detection or for use in further studies of STAT 6. Hybridization of the antisense oligonucleotides, particularly the primers and probes, of the 10 invention with a nucleic acid encoding STAT 6 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of STAT 6 in a sample may also be prepared.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art 5 for therapeutic uses. Antisense compounds have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense compounds can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the 0 treatment of cells, tissues and animals, especially humans.

For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of STAT 6 is treated by administering antisense compounds in accordance with this invention. For example, in one non-limiting embodiment, the methods comprise the step of administering to the animal in need of

-16-

treatment, a therapeutically effective amount of a STAT 6 inhibitor. The STAT 6 inhibitors of the present invention effectively inhibit the activity of the STAT 6 protein or inhibit the expression of the STAT 6 protein. In one embodiment, the activity or expression of STAT 6 (protein and/or mRNA) in an animal is inhibited by at least 10%, by at least 20%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100%.

For example, the reduction of the expression of STAT 6 may be measured in serum, adipose tissue, liver or any other body fluid, tissue or organ of the animal. In some embodiments, the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding STAT 6 protein and/or the STAT 6 protein itself.

The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the compounds and methods of the invention may also be useful prophylactically.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound, however, linear compounds are generally favorable. In addition, linear compounds may have internal nucleobase complementarity and may therefore fold in a manner as to produce a fully or partially double-stranded compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Modified Internucleoside Linkages (Backbones)

Specific examples of compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides

that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Modified oligonucleotide backbones containing a phosphorus atom therein include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

Modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677;

5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

5 *Modified sugar and internucleoside linkages-Mimetics*

In other oligonucleotide mimetics, both the sugar and the internucleoside linkage (i.e. the backbone), of the nucleotide units are replaced with novel groups. The nucleobase units are maintained for hybridization with an appropriate target nucleic acid. One such compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 10 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen *et al.*, Science, 1991, 254, 1497-1500.

In some embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- (known as a methylene (methylimino) or MMI backbone), -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- (wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-) of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also suitable are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

5 *Modified sugars*

Modified oligonucleotides may also contain one or more substituted sugar moieties. Oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particular 0 moieties also include O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl,

-19-

heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an

oligonucleotide, and other substituents having similar properties. Another modification includes

2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. Another modification includes 2'-dimethylaminoethoxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂, also described in examples hereinbelow.

Other modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. One 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,792,747; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

Another modification of the sugar includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 3' or 4' carbon atom of the sugar ring, thereby forming a bicyclic sugar moiety. The linkage is preferably a methylene (-CH₂-)_n group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2. LNAs and preparation thereof are described in WO 98/39352 and WO 99/14226.

Natural and Modified Nucleobases

Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine,

-20-

hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl ($-C\equiv C-CH_3$) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil

(pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Additional modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Additional nucleobases include those disclosed in United States Patent No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y.S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S.T. and Lebleu, B., ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2 °C and are presently suitable base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which

is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Conjugates

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve uptake, distribution, metabolism or excretion of the compounds of the present invention. Representative conjugate groups are disclosed in International Patent Application PCT/US92/09196, filed October 23, 1992, and U.S. Patent 6,287,860, the entire disclosure of which are incorporated herein by reference.

Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety. Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241; 5,391,723; 5,416,203; 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928; and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

Chimeric compounds

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide.

The present invention also includes antisense compounds that are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide-mediated inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as RNaseL which cleaves both cellular and viral RNA. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the

art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

The compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. For oligonucleotides, suitable examples of pharmaceutically acceptable salts and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.

The present invention also includes pharmaceutical compositions and formulations that include the compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-

-24-

methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations. The pharmaceutical compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.

Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the active drug that may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Microemulsions are included as an embodiment of the present invention. Emulsions and their uses are well known in the art and are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.

Formulations of the present invention include liposomal formulations. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes are positively charged liposomes that are

believed to interact with negatively charged DNA molecules to form a stable complex.

Liposomes that are pH-sensitive or negatively-charged are believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.

5 Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or
0 more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.

The pharmaceutical formulations and compositions of the present invention may also include surfactants. The use of surfactants in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Patent 6,287,860,
5 which is incorporated herein in its entirety.

In one embodiment, the present invention employs various penetration enhancers to affect the efficient delivery of nucleic acids, particularly oligonucleotides. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs. Penetration enhancers may be classified as belonging to one
0 of five broad categories, *i.e.*, surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants. Penetration enhancers and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety.

One of skill in the art will recognize that formulations are routinely designed according to their intended use, *i.e.* route of administration.

5 Formulations for topical administration include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Suitable lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and
1 cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA).

For topical or other administration, oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic

lipids. Fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999, which is incorporated herein by reference in its entirety.

5 Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. Oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration
0 enhancers surfactants and chelators. Surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Bile acids/salts and fatty acids and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety. Also suitable are combinations of penetration enhancers, for example, fatty acids/salts in combination with bile acids/salts. A particularly suitable combination is the sodium salt of lauric acid, capric acid and
5 UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents and their uses are further described in U.S. Patent 6,287,860, which is incorporated herein in its entirety. Oral formulations for oligonucleotides and their preparation
0 are described in detail in United States applications 09/108,673 (filed July 1, 1998), 09/315,298 (filed May 20, 1999) and 10/071,822, filed February 8, 2002, each of which is incorporated herein by reference in their entirety.

 Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents
5 and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

 Certain embodiments of the invention provide pharmaceutical compositions containing one or more oligomeric compounds and one or more other chemotherapeutic agents that function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not
0 limited to, cancer chemotherapeutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil,

-27-

methylnitrosourea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramide, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. Combinations of antisense compounds and other non-antisense drugs are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional compounds targeted to a second nucleic acid target. Alternatively, compositions of the invention may contain two or more compounds targeted to different regions of the same nucleic acid target. Numerous examples of compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration (dosing) is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC₅₀s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 µg to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is

-28-

administered in maintenance doses, ranging from 0.01 µg to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with specificity in accordance with certain of its embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same. Each of the references, patents, international publications, GenBank accession numbers, and the like recited in the present application are incorporated herein by reference in its entirety.

EXAMPLES

Example 1: Synthesis of Nucleoside Phosphoramidites

The following compounds, including amidites and their intermediates were prepared as described in US Patent 6,426,220 and published PCT WO 02/36743; 5'-O-Dimethoxytrityl-thymidine intermediate for 5-methyl dC amidite, 5'-O-Dimethoxytrityl-2'-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite, 5'-O-Dimethoxytrityl-2'-deoxy-N⁴-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite, [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-*N,N*-diisopropylphosphoramidite (5-methyl dC amidite), 2'-Fluorodeoxyadenosine, 2'-Fluorodeoxyguanosine, 2'-Fluorouridine, 2'-Fluorodeoxycytidine, 2'-O-(2-Methoxyethyl) modified amidites, 2'-O-(2-methoxyethyl)-5-methyluridine intermediate, 5'-O-DMT-2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate, [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridin-3'-O-yl]-2-cyanoethyl-*N,N*-diisopropylphosphoramidite (MOE T amidite), 5'-O-Dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methylcytidine intermediate, 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidine penultimate intermediate, [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-*N,N*-diisopropylphosphoramidite (MOE 5-Me-C amidite), [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyladenoin-3'-O-yl]-2-cyanoethyl-*N,N*-diisopropylphosphoramidite (MOE A amidite), [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanoin-3'-O-yl]-2-cyanoethyl-*N,N*-diisopropylphosphoramidite (MOE G amidite), 2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites, 2'-(Dimethylaminooxyethoxy) nucleoside amidites, 5'-O-*tert*-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine, 5'-O-*tert*-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine, 2'-O-([2-phthalimidooxy)ethyl]-5'-*t*-butyldiphenylsilyl-5-methyluridine, 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine,

-29-

5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N dimethylaminoxyethyl]-5-methyluridine, 2'-O-(dimethylaminoxyethyl)-5-methyluridine, 5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine, 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], 2'-(Aminoxyethoxy) nucleoside amidites, N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite], 2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites, 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine, 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]-5-methyl uridine and 5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite.

Example 2: Oligonucleotide and oligonucleoside synthesis

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

Oligonucleotides: Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

Phosphorothioates (P=S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v solution of 3,4-dihydro-2H-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages. The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH₄OAc solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Oligonucleosides: Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 3: RNA Synthesis

In general, RNA synthesis chemistry is based on the selective incorporation of various protecting groups at strategic intermediary reactions. Although one of ordinary skill in the art will understand the use of protecting groups in organic synthesis, a useful class of protecting groups includes silyl ethers. In particular bulky silyl ethers are used to protect the 5'-hydroxyl in combination with an acid-labile orthoester protecting group on the 2'-hydroxyl. This set of protecting groups is then used with standard solid-phase synthesis technology. It is important to lastly remove the acid labile orthoester protecting group after all other synthetic steps. Moreover, the early use of the silyl protecting groups during synthesis ensures facile removal when desired, without undesired deprotection of 2' hydroxyl.

-31-

Following this procedure for the sequential protection of the 5'-hydroxyl in combination with protection of the 2'-hydroxyl by protecting groups that are differentially removed and are differentially chemically labile, RNA oligonucleotides were synthesized.

RNA oligonucleotides are synthesized in a stepwise fashion. Each nucleotide is added sequentially (3'- to 5'-direction) to a solid support-bound oligonucleotide. The first nucleoside at the 3'-end of the chain is covalently attached to a solid support. The nucleotide precursor, a ribonucleoside phosphoramidite, and activator are added, coupling the second base onto the 5'-end of the first nucleoside. The support is washed and any unreacted 5'-hydroxyl groups are capped with acetic anhydride to yield 5'-acetyl moieties. The linkage is then oxidized to the more stable and ultimately desired P(V) linkage. At the end of the nucleotide addition cycle, the 5'-silyl group is cleaved with fluoride. The cycle is repeated for each subsequent nucleotide.

Following synthesis, the methyl protecting groups on the phosphates are cleaved in 30 minutes utilizing 1 M disodium-2-carbamoyl-2-cyanoethylene-1,1-dithiolate trihydrate (S_2Na_2) in DMF. The deprotection solution is washed from the solid support-bound oligonucleotide using water. The support is then treated with 40% methylamine in water for 10 minutes at 55 °C. This releases the RNA oligonucleotides into solution, deprotects the exocyclic amines, and modifies the 2'- groups. The oligonucleotides can be analyzed by anion exchange HPLC at this stage.

The 2'-orthoester groups are the last protecting groups to be removed. The ethylene glycol monoacetate orthoester protecting group developed by Dharmacon Research, Inc. (Lafayette, CO), is one example of a useful orthoester protecting group which, has the following important properties. It is stable to the conditions of nucleoside phosphoramidite synthesis and oligonucleotide synthesis. However, after oligonucleotide synthesis the oligonucleotide is treated with methylamine that not only cleaves the oligonucleotide from the solid support but also removes the acetyl groups from the orthoesters. The resulting 2-ethyl-hydroxyl substituents on the orthoester are less electron withdrawing than the acetylated precursor. As a result, the modified orthoester becomes more labile to acid-catalyzed hydrolysis. Specifically, the rate of cleavage is approximately 10 times faster after the acetyl groups are removed. Therefore, this orthoester possesses sufficient stability in order to be compatible with oligonucleotide synthesis and yet, when subsequently modified, permits deprotection to be carried out under relatively mild aqueous conditions compatible with the final RNA oligonucleotide product.

Additionally, methods of RNA synthesis are well known in the art (Scaringe, S. A. Ph.D. Thesis, University of Colorado, 1996; Scaringe, S. A., et al., J. Am. Chem. Soc., 1998, 120, 11820-11821; Matteucci, M. D. and Caruthers, M. H. J. Am. Chem. Soc., 1981, 103, 3185-3191; Beaucage, S. L. and Caruthers, M. H. Tetrahedron Lett., 1981, 22, 1859-1862; Dahl, B. J.,

et al., Acta Chem. Scand., 1990, 44, 639-641; Reddy, M. P., et al., Tetrahedron Lett., 1994, 25, 4311-4314; Wincott, F. et al., Nucleic Acids Res., 1995, 23, 2677-2684; Griffin, B. E., et al., Tetrahedron, 1967, 23, 2301-2313; and Griffin, B. E., et al., Tetrahedron, 1967, 23, 2315-2331).

RNA antisense compounds (RNA oligonucleotides) of the present invention can be synthesized by the methods herein or purchased from Dharmacon Research, Inc (Lafayette, CO). Once synthesized, complementary RNA antisense compounds can then be annealed by methods known in the art to form double stranded (duplexed) antisense compounds. For example, duplexes can be formed by combining 30 μ l of each of the complementary strands of RNA oligonucleotides (50 μ M RNA oligonucleotide solution) and 15 μ l of 5X annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate) followed by heating for 1 minute at 90°C, then 1 hour at 37°C. The resulting duplexed antisense compounds can be used in kits, assays, screens, or other methods to investigate the role of a target nucleic acid.

Example 4: Synthesis of Chimeric Oligonucleotides

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers."

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above. Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH₄OH) for 12-16 hr at 55°C. The deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography, volume reduced *in vacuo* and analyzed

-33-

spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry).

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

5 [2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

0 [2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the
5 phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dihydro-2H-benzothio-1,2-dioxole 1,1-dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065,
0 herein incorporated by reference.

Example 5: Design and screening of duplexed antisense compounds targeting STAT 6

In accordance with the present invention, a series of nucleic acid duplexes comprising the antisense compounds of the present invention and their complements can be designed to
5 target STAT 6. The nucleobase sequence of the antisense strand of the duplex comprises at least an 8-nucleobase portion of an oligonucleotide in Table 1. The ends of the strands may be modified by the addition of one or more natural or modified nucleobases to form an overhang. The sense strand of the dsRNA is then designed and synthesized as the complement of the antisense strand and may also contain modifications or additions to either terminus. For example,
0 in one embodiment, both strands of the dsRNA duplex would be complementary over the central nucleobases, each having overhangs at one or both termini.

For example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGGACCG (SEQ ID NO:139) and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

-34-

cgagaggcggacgggaccgTT	(SEQ ID NO:140)	Antisense Strand
TTgctctccgcctgcctggc	(SEQ ID NO:141)	Complement

5 RNA strands of the duplex can be synthesized by methods disclosed herein or
purchased from Dharmacon Research Inc., (Lafayette, CO). Once synthesized, the
complementary strands are annealed. The single strands are aliquoted and diluted to a
concentration of 50 μ M. Once diluted, 30 μ L of each strand is combined with 15 μ L of a 5X
solution of annealing buffer. The final concentration of said buffer is 100 mM potassium acetate,
0 30 mM HEPES-KOH pH 7.4, and 2 mM magnesium acetate. The final volume is 75 μ L. This
solution is incubated for 1 minute at 90°C and then centrifuged for 15 seconds. The tube is
allowed to sit for 1 hour at 37°C at which time the dsRNA duplexes are used in experimentation.
The final concentration of the dsRNA duplex is 20 μ M. This solution can be stored frozen (at,
for example, -20°C) and freeze-thawed up to 5 times.

5 Once prepared, the duplexed antisense compounds are evaluated for their ability to
modulate STAT 6 expression.

When cells reached 80% confluency, they are treated with duplexed antisense
compounds of the invention. For cells grown in 96-well plates, wells are washed once with 200
 μ L OPTI-MEM-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-
0 MEM-1 containing 12 μ g/mL LIPOFECTIN (Gibco BRL) and the desired duplex antisense
compound at a final concentration of 200 nM. After 5 hours of treatment, the medium is replaced
with fresh medium. Cells are harvested 16 hours after treatment, at which time RNA is isolated
and target reduction measured by RT-PCR.

5 **Example 6: Oligonucleotide Isolation**

After cleavage from the controlled pore glass solid support and deblocking in
concentrated ammonium hydroxide at 55°C for 12-16 hours, the oligonucleotides or
oligonucleosides are recovered by precipitation out of 1 M NH_4OAc with >3 volumes of ethanol.
Synthesized oligonucleotides were analyzed by electrospray mass spectroscopy (molecular
1 weight determination) and by capillary gel electrophoresis and judged to be at least 70% full
length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained
in the synthesis was determined by the ratio of correct molecular weight relative to the -16 amu
product (+/-32 +/-48). For some studies oligonucleotides were purified by HPLC, as described
by Chiang et al., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified
material were similar to those obtained with non-HPLC purified material.

Example 7: Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine.

5 Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as
0 base protected beta-cyanoethyldiisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried *in vacuo*. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

5

Example 8: Oligonucleotide Analysis – 96-Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96-well format (Beckman P/ACE™
0 MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

5

Example 9: Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels.

This can be routinely determined using, for example, PCR or Northern blot analysis. The

) following cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

-36-

T-24 cells: The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #353872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells: The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells: Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells: Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

Treatment with antisense compounds: When cells reached 65-75% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 100 μ L OPTI-MEMTM-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μ L of OPTI-MEMTM-1 containing 3.75 μ g/mL LIPOFECTINTM (Invitrogen Corporation, Carlsbad, CA) and the desired concentration of oligonucleotide. Cells are treated and data are obtained in triplicate. After 4-7 hours of treatment at 37°C, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

-37-

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is selected from either ISIS 13920 (**TCCGTCATCGCTCCTCAGGG**, SEQ ID NO:1) which is targeted to human H-ras, or ISIS 18078, (**GTGCGCGCGAGCCCGAAATC**, SEQ ID NO:2) which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2'-O-methoxyethyl gapmers (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 3, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-H-ras (for ISIS 13920), JNK2 (for ISIS 18078) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of c-H-ras, JNK2 or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

Example 10: Analysis of oligonucleotide inhibition of STAT 6 expression

Antisense modulation of STAT 6 expression can be assayed in a variety of ways known in the art. For example, STAT 6 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently favorable. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. A method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are well known in the art. Northern blot analysis is also routine in the art. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7600, 7700, or 7900 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of STAT 6 can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), enzyme-linked immunosorbent assay (ELISA) or fluorescence-activated cell sorting (FACS). Antibodies

directed to STAT 6 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional monoclonal or polyclonal antibody generation methods well known in the art.

5 **Example 11: Design of phenotypic assays and *in vivo* studies for the use of STAT 6 inhibitors**

Phenotypic assays

Once STAT 6 inhibitors have been identified by the methods disclosed herein, the compounds are further investigated in one or more phenotypic assays, each having measurable
0 endpoints predictive of efficacy in the treatment of a particular disease state or condition.

Phenotypic assays, kits and reagents for their use are well known to those skilled in the art and are herein used to investigate the role and/or association of STAT 6 in health and disease. Representative phenotypic assays, which can be purchased from any one of several commercial vendors, include those for determining cell viability, cytotoxicity, proliferation or cell survival
5 (Molecular Probes, Eugene, OR; PerkinElmer, Boston, MA), protein-based assays including enzymatic assays (Panvera, LLC, Madison, WI; BD Biosciences, Franklin Lakes, NJ; Oncogene Research Products, San Diego, CA), cell regulation, signal transduction, inflammation, oxidative processes and apoptosis (Assay Designs Inc., Ann Arbor, MI), triglyceride accumulation (Sigma-Aldrich, St. Louis, MO), angiogenesis assays, tube formation assays, cytokine and hormone
10 assays and metabolic assays (Chemicon International Inc., Temecula, CA; Amersham Biosciences, Piscataway, NJ).

In one non-limiting example, cells determined to be appropriate for a particular phenotypic assay (i.e., MCF-7 cells selected for breast cancer studies; adipocytes for obesity studies) are treated with STAT 6 inhibitors identified from the *in vitro* studies as well as control
15 compounds at optimal concentrations which are determined by the methods described above. At the end of the treatment period, treated and untreated cells are analyzed by one or more methods specific for the assay to determine phenotypic outcomes and endpoints.

Phenotypic endpoints include changes in cell morphology over time or treatment dose as well as changes in levels of cellular components such as proteins, lipids, nucleic acids,
20 hormones, saccharides or metals. Measurements of cellular status which include pH, stage of the cell cycle, intake or excretion of biological indicators by the cell, are also endpoints of interest.

Analysis of the genotype of the cell (measurement of the expression of one or more of the genes of the cell) after treatment is also used as an indicator of the efficacy or potency of the

STAT 6 inhibitors. Hallmark genes, or those genes suspected to be associated with a specific disease state, condition, or phenotype, are measured in both treated and untreated cells.

In vivo studies

The individual subjects of the *in vivo* studies described herein are warm-blooded vertebrate animals, which includes humans.

The clinical trial is subjected to rigorous controls to ensure that individuals are not unnecessarily put at risk and that they are fully informed about their role in the study.

To account for the psychological effects of receiving treatments, volunteers are randomly given placebo or STAT 6 inhibitor. Furthermore, to prevent the doctors from being biased in treatments, they are not informed as to whether the medication they are administering is a STAT 6 inhibitor or a placebo. Using this randomization approach, each volunteer has the same chance of being given either the new treatment or the placebo.

Volunteers receive either the STAT 6 inhibitor or placebo for eight week period with biological parameters associated with the indicated disease state or condition being measured at the beginning (baseline measurements before any treatment), end (after the final treatment), and at regular intervals during the study period. Such measurements include the levels of nucleic acid molecules encoding STAT 6 or STAT 6 protein levels in body fluids, tissues or organs compared to pre-treatment levels. Other measurements include, but are not limited to, indices of the disease state or condition being treated, body weight, blood pressure, serum titers of pharmacologic indicators of disease or toxicity as well as ADME (absorption, distribution, metabolism and excretion) measurements.

Information recorded for each patient includes age (years), gender, height (cm), family history of disease state or condition (yes/no), motivation rating (some/moderate/great) and number and type of previous treatment regimens for the indicated disease or condition.

Volunteers taking part in this study are healthy adults (age 18 to 65 years) and roughly an equal number of males and females participate in the study. Volunteers with certain characteristics are equally distributed for placebo and STAT 6 inhibitor treatment. In general, the volunteers treated with placebo have little or no response to treatment, whereas the volunteers treated with the STAT 6 inhibitor show positive trends in their disease state or condition index at the conclusion of the study.

Example 12: RNA Isolation

Poly(A)+ mRNA isolation

-40-

Poly(A)+ mRNA was isolated according to Miura et al., (Clin. Chem., 1996, 42, 1758-1764). Other methods for poly(A)+ mRNA isolation are routine in the art. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C, was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 150 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 150 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 1 minute. 500 μ L of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for 15 minutes and the vacuum was again applied for 1 minute. An additional 500 μ L of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 140 μ L of RNase free water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

5

Example 13: Real-time Quantitative PCR Analysis of STAT 6 mRNA Levels

Quantitation of STAT 6 mRNA levels was accomplished by real-time quantitative PCR using the ABI PRISM™ 7600, 7700, or 7900 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system that allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells

-42-

is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, CA). RT-PCR reactions were carried out by adding 20 μ L PCR cocktail (2.5x PCR buffer minus $MgCl_2$, 6.6 mM $MgCl_2$, 375 μ M each of dATP, dCTP, dCTP and dGTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 μ L total RNA solution (20-200 ng). The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreen™ RNA quantification reagent (Molecular Probes, Inc. Eugene, OR). Methods of RNA quantification by RiboGreen™ are taught in Jones, L.J., et al, (Analytical Biochemistry, 1998, 265, 368-374).

In this assay, 170 μ L of RiboGreen™ working reagent (RiboGreen™ reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 μ L purified, cellular RNA. The plate is read in a CytoFluor 4000 (PE Applied Biosystems) with excitation at 485nm and emission at 530nm.

Probes and primers to human STAT 6 were designed to hybridize to a human STAT 6 sequence, using published sequence information (GenBank accession number NM_003153.1, incorporated herein as SEQ ID NO:4). For human STAT 6 the PCR primers were:

forward primer: CCAAACGCTGTCTCCGGA (SEQ ID NO:5)

reverse primer: GCTAGTAACGTACTGTTTGCTGATGAA (SEQ ID NO:6)

and the PCR probe was:

-43-

FAM-CTACTGGTCTGACCGGCTGATCATTGG-TAMRA (SEQ ID NO:7)

where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:8)

reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO:9)

and the PCR probe was:

5' JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3' (SEQ ID NO:10)

where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

0 **Example 14: Northern blot analysis of STAT 6 mRNA levels**

Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST “B” Inc., Friendswood, TX). Total RNA was prepared following manufacturer’s recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, OH). RNA was transferred from the gel to HYBOND™-N+ nylon membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST “B” Inc., Friendswood, TX). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, CA) using manufacturer’s recommendations for stringent conditions.

To detect human STAT 6, a human STAT 6 specific probe was prepared by PCR using the forward primer CCAAACGCTGTCTCCGGA (SEQ ID NO:5) and the reverse primer GCTAGTAACGTACTGTTTGCTGATGAA (SEQ ID NO:6). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15: Antisense inhibition of human STAT 6 expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of antisense compounds were designed to target different regions of the human STAT 6 RNA, using published sequences

-44-

(GenBank accession number NM_003153.1, incorporated herein as SEQ ID NO:4; GenBank accession number BC005823.1, incorporated herein as SEQ ID NO:11; a genomic sequence of human STAT 6 represented by the complement of residues 157501-174000 of GenBank accession number AC018673.4, incorporated herein as SEQ ID NO:12; GenBank accession number BE972840.1, the complement of which is incorporated herein as SEQ ID NO:13; and GenBank accession number BF902909.1, the complement of which is incorporated herein as SEQ ID NO:14). The compounds are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the compound binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings." The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human STAT 6 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from three experiments in which T-24 cells were treated with the oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data."

Table 1

Inhibition of human STAT 6 mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
153765	Coding	4	1951	agtgagcgaatggacaggctc	96	15	2
153766	Coding	4	2483	cgctgtcactggctggctca	83	16	2
153767	Coding	4	1171	ttgatgatttctccagtgct	92	17	2
153768	Coding	4	940	aggacttcacccagccggcc	50	18	2
153769	Coding	4	1054	cccaggaacctcaagcccaa	68	19	2
153770	Coding	4	242	gtcacccagaagatgccgca	53	20	2
153771	Coding	4	2100	ttccacggatcatcttgatg	59	21	2
153772	Coding	4	379	aagatgggtgctcccctccc	34	22	2
153773	Coding	4	765	gcggttccaaatctggatc	76	23	2
153774	Coding	4	729	cttggctgcctctagctct	89	24	2
153775	Coding	4	1725	gtttggtgaggtccaggaca	89	25	2
153776	Coding	4	2321	catctgcaggtgaggctcct	85	26	2
153777	Coding	4	2676	tggcccttaggtccatgtgg	76	27	2
153778	Coding	4	1905	ctatctgtggagagccatcc	72	28	2
153779	Coding	4	1805	attgagaagaaggctagtaa	83	29	2
153780	Coding	4	392	gctgatgtgtgtcaagatgg	78	30	2
153781	3'UTR	4	3019	gccccatcacccctcagagag	80	31	2
153782	Coding	4	417	ccctctgatatatgtctca	73	32	2
153783	Coding	4	1797	gaaggctagtaacgtactgt	84	33	2
153784	Coding	4	1819	gtccgctcgggctcattgag	92	34	2

-45-

153785	Coding	4	2479	gtcactggctggctcaggca	87	35	2
153786	Coding	4	1513	ttcagagtttcacacatctt	83	36	2
153787	5'UTR	4	79	caggccccataggtctgtag	88	37	2
153788	Coding	4	644	tatcaagctgtgcagagaca	80	38	2
153789	Coding	4	272	caggaaactcccagggtggc	74	39	2
153790	3'UTR	4	3000	gctctgtatgtgtgtgtgcg	90	40	2
153791	Coding	4	1972	agatcccggattcggctccc	88	41	2
153792	Coding	4	794	cgggtgcgccattccctgccca	94	42	2
153793	Coding	4	1997	gggatagagattttgagct	53	43	2
153794	Start Codon	4	146	gatctgggacttggagggtg	71	44	2
153795	Coding	4	2165	tccaaggtcataagaaggca	88	45	2
153796	Coding	4	1762	atgatcagccggctcagacca	84	46	2
153797	Coding	4	1205	cccagggaatgctgttctcca	88	47	2
153798	Coding	4	944	tctcaggacttcatccagcc	6	48	2
153799	Coding	4	1671	ccagcaggatctcctgttg	82	49	2
153800	Coding	4	1160	tccagtgccttctgctccag	87	50	2
153801	Coding	4	328	acagtgtctgaaagtagggc	50	51	2
195427	5'UTR	4	39	gctggccctgctagcacctc	68	52	2
195428	Start Codon	4	158	ccacagagacatgatctggg	79	53	2
195429	Coding	4	541	gtcttaacttgagtcttc	53	54	2
195430	Coding	4	718	tctagctctccagtgtctc	78	55	2
195431	Coding	4	1085	ggccctgaccagcggagget	72	56	2
195432	Coding	4	1290	cctctgtgacagactcagtg	72	57	2
195433	Coding	4	1615	tccatactgaggctgtgttc	20	58	2
195434	Coding	4	1887	cctggccccggatgacatgg	53	59	2
195435	Coding	4	2152	gaaggcaccatggttaggc	55	60	2
195436	Coding	4	2506	ccaatccaagtgcctgagg	70	61	2
195437	Stop Codon	4	2699	cagctgggatcaccaactgg	49	62	2
195438	3'UTR	4	2944	gtgtctcagagcctgaactt	77	63	2
195439	5'UTR	11	23	taagcagtggctgcccagc	51	64	2
195440	5'UTR	11	38	cctccctcttcagtgtatgc	65	65	2
195441	3'UTR	11	3185	agaagccttccatgccctaa	83	66	2
195442	3'UTR	11	3230	tatgttcctgcctatccgtc	76	67	2
195443	3'UTR	11	3531	caactaagggtgccagctata	86	68	2
195444	3'UTR	11	3539	tggcatgcaactaagggtgc	84	69	2
195445	3'UTR	11	3585	atttgtgtgtcacgtaggc	84	70	2
195446	3'UTR	11	3599	tctcacctcccaattgt	48	71	2
195447	3'UTR	11	3629	agcacactgtctgtctt	74	72	2
195448	3'UTR	11	3779	gccaggcctggaccagact	60	73	2
195449	3'UTR	11	3835	gggcaacagaaaagatgcag	50	74	2
195450	Intron	12	2812	aatgtcagcttttaactgt	67	75	2
195451	Intron	12	3082	gagtcfaatgcctgagatggg	50	76	2
195452	Intron: Exon Junction	12	6200	caggaaagcaactgggagtga	7	77	2
195453	Exon: Intron Junction	12	8677	ccatctcagagaaggcattg	81	78	2
195454	Intron	12	10476	tgcacatgtccctgtgggat	64	79	2
195455	Exon: Intron Junction	12	11486	gggactcaccggtcagacca	26	80	2
195456	Intron: Exon Junction	12	12582	agtgggtgtccctggagga	71	81	2
195457	Exon: Intron Junction	12	12691	agctccttacaccatatctg	0	82	2
195458	Genomic	13	9	caaagtgtggaagtgaagg	0	83	2

-46-

195459	Genomic	13	148	ctctggtggccacggtggga	0	84	2
195460	Genomic	13	654	ggtgtatggtgctcagact	67	85	2
195461	Genomic	14	66	aggaggtacatgtgactgac	23	86	2

As shown in Table 1, SEQ ID NOs:15, 16, 17, 19, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 45, 46, 47, 49, 50, 52, 53, 55, 56, 57, 61, 63, 65, 66, 67, 68, 69, 70, 72, 73, 75, 78, 79, 81 and 85 demonstrated at least 60% inhibition of human STAT 6 expression in this assay and are therefore suitable. SEQ ID NOs:15, 34 and 42 showed the best results. The target regions to which these suitable sequences are complementary are herein referred to as "suitable target segments" and are therefore suitable for targeting by compounds of the present invention. These suitable target segments are shown in Table 2. The sequences represent the reverse complement of the suitable antisense compounds shown in Table 1.

"Target site" indicates the first (5'-most) nucleotide number on the particular target nucleic acid to which the oligonucleotide binds. Also shown in Table 2 is the species in which each of the suitable target segments was found.

Table 2
Sequence and position of suitable target segments identified in STAT 6.

SITEID	TARGET SEQ ID NO	TARGE T SITE	SEQUENCE	REV COMP OF SEQ ID	ACTIVE IN	SEQ ID NO
69306	4	1951	gacctgtccattcgctcact	15	<i>H. sapiens</i>	87
69307	4	2483	tgagccagccagtgacagcg	16	<i>H. sapiens</i>	88
69308	4	1171	agcactggagaaatcatcaa	17	<i>H. sapiens</i>	89
69310	4	1054	ttgggcttgagggttcctggg	19	<i>H. sapiens</i>	90
69314	4	765	gatccagattggaacggc	23	<i>H. sapiens</i>	91
69315	4	729	agagctagaggcagccaaag	24	<i>H. sapiens</i>	92
69316	4	1725	tgtcctggacctcacaaac	25	<i>H. sapiens</i>	93
69317	4	2321	aggagcctcacctgcagatg	26	<i>H. sapiens</i>	94
69318	4	2676	ccacatggacctaagggccca	27	<i>H. sapiens</i>	95
69319	4	1905	ggatggctctccacagatag	28	<i>H. sapiens</i>	96
69320	4	1805	ttactagccttcttcaat	29	<i>H. sapiens</i>	97
69321	4	392	ccatcttgcaacacatcagc	30	<i>H. sapiens</i>	98
69322	4	3019	ctctctgagggtgatggggc	31	<i>H. sapiens</i>	99
69323	4	417	tgagagcatatatacagagg	32	<i>H. sapiens</i>	100
69324	4	1797	acagtacgttactagccttc	33	<i>H. sapiens</i>	101
69325	4	1819	ctcaatgagcccacggaac	34	<i>H. sapiens</i>	102
69326	4	2479	tgctgagccagccagtgac	35	<i>H. sapiens</i>	103
69327	4	1513	aagatgtgtgaaactctgaa	36	<i>H. sapiens</i>	104
69328	4	79	ctacagacctatggggcctg	37	<i>H. sapiens</i>	105
69329	4	644	tgtctctgcacagcttgata	38	<i>H. sapiens</i>	106
69330	4	272	gccagccctgggagtctctg	39	<i>H. sapiens</i>	107
69331	4	3000	cgcacacacatacagagc	40	<i>H. sapiens</i>	108
69332	4	1972	ggggaccgaatccgggatct	41	<i>H. sapiens</i>	109
69333	4	794	tggcaggggaatggcgaccg	42	<i>H. sapiens</i>	110
69335	4	146	caactccaagtcccagatc	44	<i>H. sapiens</i>	111
69336	4	2165	tgcttcttatgaccttga	45	<i>H. sapiens</i>	112
69337	4	1762	tggctgaccggctgatcat	46	<i>H. sapiens</i>	113
69338	4	1205	tggagaacagcattctctggg	47	<i>H. sapiens</i>	114
69340	4	1671	caacaaggagatcctgctgg	49	<i>H. sapiens</i>	115

-47-

69341	4	1160	ctggagcagaaagcactgga	50	<i>H. sapiens</i>	116
113659	4	39	gaggtgctagcagggccagc	52	<i>H. sapiens</i>	117
113660	4	158	cccagatcatgtctctgtgg	53	<i>H. sapiens</i>	118
113662	4	718	gagaccactggagagctaga	55	<i>H. sapiens</i>	119
113663	4	1085	agcctccgctggtcagggcc	56	<i>H. sapiens</i>	120
113664	4	1290	cactgagctgtcacagagg	57	<i>H. sapiens</i>	121
113668	4	2506	cctcagggcacttgattgg	61	<i>H. sapiens</i>	122
113670	4	2944	aagttcaggctctgagacac	63	<i>H. sapiens</i>	123
113672	11	38	gcttacactgaagaggagg	65	<i>H. sapiens</i>	124
113673	11	3185	ttagggcatggaaggctct	66	<i>H. sapiens</i>	125
113674	11	3230	gacggataggcaggaacata	67	<i>H. sapiens</i>	126
113675	11	3531	tatagctggcaccttagttg	68	<i>H. sapiens</i>	127
113676	11	3539	gcaccttagttgcatgacca	69	<i>H. sapiens</i>	128
113677	11	3585	gcctacgtgacaacacaaat	70	<i>H. sapiens</i>	129
113679	11	3629	aagacagcagcaagtgtgct	72	<i>H. sapiens</i>	130
113680	11	3779	agtctgggtccaggcctggc	73	<i>H. sapiens</i>	131
113682	12	2812	acagattaaaagctgacatt	75	<i>H. sapiens</i>	132
113685	12	8677	caatgccttctctgagatgg	78	<i>H. sapiens</i>	133
113686	12	10476	atccacagggacatgtgca	79	<i>H. sapiens</i>	134
113688	12	12582	tcctccagggaccaaccact	81	<i>H. sapiens</i>	135
113692	13	654	agtctgagcagccatacacc	85	<i>H. sapiens</i>	136

As these "suitable target segments" have been found by experimentation to be open to, and accessible for, hybridization with the antisense compounds of the present invention, one of skill in the art will recognize or be able to ascertain, using no more than routine experimentation, further embodiments of the invention that encompass other compounds that specifically hybridize to these suitable target segments and consequently inhibit the expression of STAT 6.

According to the present invention, antisense compounds include antisense oligomeric compounds, antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other short oligomeric compounds which hybridize to at least a portion of the target nucleic acid.

Example 16: Western blot analysis of STAT 6 protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to STAT 6 is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

Example 17: Targeting of individual oligonucleotides to specific variants of STAT 6

It is advantageous to selectively inhibit the expression of one or more variants of STAT

6. Consequently, in one embodiment of the present invention are oligonucleotides that selectively target, hybridize to, and specifically inhibit one or more, but fewer than all of the

variants of STAT 6. A summary of the target sites of the variants is shown in Table 3 and

includes GenBank accession number BC005823.1, representing STAT 6 main mRNA

(represented in Table 3 as STAT 6), incorporated herein as SEQ ID NO:11; GenBank accession

number BE972840.1, representing STAT 6d, incorporated herein as SEQ ID NO:13; GenBank

accession number BF902909.1, representing STAT 6e, incorporated herein as SEQ ID NO:14;

GenBank accession number AR204914.1, representing STAT 6b, incorporated herein as SEQ ID

NO:137; and GenBank accession number AR204915.1, representing STAT 6c, incorporated

herein as SEQ ID NO:138.

Table 3**Targeting of individual oligonucleotides to specific variants of STAT 6**

ISIS #	OLIGO SEQ ID NO.	TARGET SITE	VARIANT	VARIANT SEQ ID NO.
153765	15	2066	STAT 6	11
153765	15	1932	STAT 6c	137
153765	15	1741	STAT 6b	138
153766	16	2597	STAT 6	11
153766	16	2464	STAT 6c	137
153766	16	2273	STAT 6b	138
153767	17	1286	STAT 6	11
153767	17	1236	STAT 6c	137
153767	17	961	STAT 6b	138
153768	18	1055	STAT 6	11
153768	18	1005	STAT 6c	137
153768	18	730	STAT 6b	138
153769	19	1169	STAT 6	11
153769	19	1119	STAT 6c	137
153769	19	844	STAT 6b	138
153770	20	357	STAT 6	11
153770	20	307	STAT 6c	137
153770	20	171	STAT 6b	138
153771	21	2215	STAT 6	11
153771	21	2081	STAT 6c	137
153771	21	1890	STAT 6b	138
153772	22	494	STAT 6	11
153772	22	444	STAT 6c	137
153773	23	880	STAT 6	11
153773	23	830	STAT 6c	137
153773	23	555	STAT 6b	138
153774	24	844	STAT 6	11
153774	24	794	STAT 6c	137
153774	24	519	STAT 6b	138
153775	25	1840	STAT 6	11
153775	25	1790	STAT 6c	137
153775	25	1515	STAT 6b	138
153776	26	2435	STAT 6	11

-49-

153776	26	298	STAT 6e	14
153776	26	2302	STAT 6c	137
153776	26	2111	STAT 6b	138
153777	27	2790	STAT 6	11
153777	27	2657	STAT 6c	137
153777	27	2466	STAT 6b	138
153778	28	2020	STAT 6	11
153778	28	1886	STAT 6c	137
153778	28	1695	STAT 6b	138
153779	29	1920	STAT 6	11
153779	29	1595	STAT 6b	138
153780	30	507	STAT 6	11
153780	30	457	STAT 6c	137
153781	31	3133	STAT 6	11
153781	31	3000	STAT 6c	137
153781	31	2809	STAT 6b	138
153782	32	532	STAT 6	11
153782	32	482	STAT 6c	137
153783	33	1912	STAT 6	11
153783	33	1587	STAT 6b	138
153784	34	1934	STAT 6	11
153784	34	1609	STAT 6b	138
153785	35	2593	STAT 6	11
153785	35	2460	STAT 6c	137
153785	35	2269	STAT 6b	138
153786	36	1628	STAT 6	11
153786	36	377	STAT 6d	13
153786	36	1578	STAT 6c	137
153786	36	1303	STAT 6b	138
153787	37	194	STAT 6	11
153787	37	76	STAT 6c	137
153787	37	8	STAT 6b	138
153788	38	759	STAT 6	11
153788	38	709	STAT 6c	137
153788	38	434	STAT 6b	138
153789	39	387	STAT 6	11
153789	39	337	STAT 6c	137
153790	40	3114	STAT 6	11
153790	40	2981	STAT 6c	137
153790	40	2790	STAT 6b	138
153791	41	2087	STAT 6	11
153791	41	1953	STAT 6c	137
153791	41	1762	STAT 6b	138
153792	42	909	STAT 6	11
153792	42	859	STAT 6c	137
153792	42	584	STAT 6b	138
153793	43	2112	STAT 6	11
153793	43	1978	STAT 6c	137
153793	43	1787	STAT 6b	138
153794	44	261	STAT 6	11
153794	44	211	STAT 6c	137
153794	44	75	STAT 6b	138
153795	45	2280	STAT 6	11
153795	45	142	STAT 6e	14
153795	45	2146	STAT 6c	137
153795	45	1955	STAT 6b	138
153796	46	1877	STAT 6	11
153796	46	1552	STAT 6b	138
153797	47	1320	STAT 6	11

-50-

153797	47	1270	STAT 6c	137
153797	47	995	STAT 6b	138
153798	48	1059	STAT 6	11
153798	48	1009	STAT 6c	137
153798	48	734	STAT 6b	138
153799	49	1786	STAT 6	11
153799	49	535	STAT 6d	13
153799	49	1736	STAT 6c	137
153799	49	1461	STAT 6b	138
153800	50	1275	STAT 6	11
153800	50	1225	STAT 6c	137
153800	50	950	STAT 6b	138
153801	51	443	STAT 6	11
153801	51	393	STAT 6c	137
195427	52	154	STAT 6	11
195427	52	36	STAT 6c	137
195428	53	273	STAT 6	11
195428	53	223	STAT 6c	137
195428	53	87	STAT 6b	138
195429	54	656	STAT 6	11
195429	54	606	STAT 6c	137
195429	54	331	STAT 6b	138
195430	55	833	STAT 6	11
195430	55	783	STAT 6c	137
195430	55	508	STAT 6b	138
195431	56	1200	STAT 6	11
195431	56	1150	STAT 6c	137
195431	56	875	STAT 6b	138
195432	57	1405	STAT 6	11
195432	57	1355	STAT 6c	137
195432	57	1080	STAT 6b	138
195433	58	1730	STAT 6	11
195433	58	479	STAT 6d	13
195433	58	1680	STAT 6c	137
195433	58	1405	STAT 6b	138
195434	59	2002	STAT 6	11
195434	59	1868	STAT 6c	137
195434	59	1677	STAT 6b	138
195435	60	2267	STAT 6	11
195435	60	129	STAT 6e	14
195435	60	2133	STAT 6c	137
195435	60	1942	STAT 6b	138
195436	61	2620	STAT 6	11
195436	61	2487	STAT 6c	137
195436	61	2296	STAT 6b	138
195437	62	2813	STAT 6	11
195437	62	2680	STAT 6c	137
195437	62	2489	STAT 6b	138
195438	63	3058	STAT 6	11
195438	63	2925	STAT 6c	137
195438	63	2734	STAT 6b	138
195439	64	23	STAT 6	11
195440	65	38	STAT 6	11
195441	66	3185	STAT 6	11
195441	66	3052	STAT 6c	137
195441	66	2861	STAT 6b	138
195442	67	3230	STAT 6	11
195442	67	3097	STAT 6c	137
195442	67	2906	STAT 6b	138

-51-

195443	68	3531	STAT 6	11
195443	68	3398	STAT 6c	137
195443	68	3207	STAT 6b	138
195444	69	3539	STAT 6	11
195444	69	3406	STAT 6c	137
195444	69	3215	STAT 6b	138
195445	70	3585	STAT 6	11
195445	70	3452	STAT 6c	137
195445	70	3261	STAT 6b	138
195446	71	3599	STAT 6	11
195446	71	3466	STAT 6c	137
195446	71	3275	STAT 6b	138
195447	72	3629	STAT 6	11
195447	72	3496	STAT 6c	137
195447	72	3305	STAT 6b	138
195448	73	3779	STAT 6	11
195448	73	3646	STAT 6c	137
195448	73	3455	STAT 6b	138
195449	74	3835	STAT 6	11
195449	74	3702	STAT 6c	137
195449	74	3511	STAT 6b	138
195453	78	1567	STAT 6	11
195453	78	1517	STAT 6c	137
195453	78	1242	STAT 6b	138
195455	80	624	STAT 6d	13
195456	81	90	STAT 6e	14
195458	83	9	STAT 6d	13
195459	84	148	STAT 6d	13
195460	85	654	STAT 6d	13
195461	86	66	STAT 6e	14

What is claimed is:

1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding STAT 6, wherein the compound specifically hybridizes with the nucleic acid molecule encoding STAT 6 (SEQ ID NO:4) and inhibits the expression of STAT 6.
2. The compound of claim 1 comprising 12 to 50 nucleobases in length.
3. The compound of claim 2 comprising 15 to 30 nucleobases in length.
4. The compound of claim 1 comprising an oligonucleotide.
5. The compound of claim 4 comprising an antisense oligonucleotide.
6. The compound of claim 4 comprising a DNA oligonucleotide.
7. The compound of claim 4 comprising an RNA oligonucleotide.
8. The compound of claim 4 comprising a chimeric oligonucleotide.
9. The compound of claim 4 wherein at least a portion of the compound hybridizes with RNA to form an oligonucleotide-RNA duplex.
10. The compound of claim 1 having at least 70% complementarity with a nucleic acid molecule encoding STAT 6 (SEQ ID NO:4) the compound specifically hybridizing to and inhibiting the expression of STAT 6.
11. The compound of claim 1 having at least 80% complementarity with a nucleic acid molecule encoding STAT 6 (SEQ ID NO:4) the compound specifically hybridizing to and inhibiting the expression of STAT 6.
12. The compound of claim 1 having at least 90% complementarity with a nucleic acid molecule encoding STAT 6 (SEQ ID NO:4) the compound specifically hybridizing to and inhibiting the expression of STAT 6.
13. The compound of claim 1 having at least 95% complementarity with a nucleic acid molecule encoding STAT 6 (SEQ ID NO:4) the compound specifically hybridizing to and inhibiting the expression of STAT 6.
14. The compound of claim 1 having at least one modified internucleoside linkage, sugar moiety, or nucleobase.
15. The compound of claim 1 having at least one 2'-O-methoxyethyl sugar moiety.
16. The compound of claim 1 having at least one phosphorothioate internucleoside linkage.
17. The compound of claim 1 having at least one 5-methylcytosine.
18. The compound of claim 1 wherein the compound specifically hybridizes to the 5' untranslated region, the start codon region, the coding region, the stop codon region, or the 3' untranslated region of the nucleic acid molecule encoding STAT 6.

19. The compound of claim 1 wherein the compound specifically hybridizes to the 5' untranslated region.
20. The compound of claim 1 wherein the compound specifically hybridizes to the start codon region.
21. The compound of claim 1 wherein the compound specifically hybridizes to the coding region.
22. The compound of claim 1 wherein the compound specifically hybridizes to the stop codon region.
23. The compound of claim 1 wherein the compound specifically hybridizes to the 3' untranslated region.
24. The compound of claim 1 wherein the compound comprises SEQ ID NO:15, 34, 42, 16, 17, 19, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 35, 36, 37, 38, 39, 40, 41, 44, 45, 46, 47, 49, 50, 52, 53, 55, 56, 57, 61, or 63.
25. The compound of claim 1 wherein the compound comprises SEQ ID NO:15, 34, or 42.
26. A method of inhibiting the expression of STAT 6 in cells or tissues comprising contacting the cells or tissues with the compound of claim 1 so that expression of STAT 6 is inhibited.
27. A method of screening for a modulator of STAT 6, the method comprising the steps of:
contacting a suitable target segment of a nucleic acid molecule encoding STAT 6 with one or more candidate modulators of STAT 6; and
identifying one or more modulators of STAT 6 expression which modulate the expression of STAT 6.
28. The method of claim 27 wherein the modulator of STAT 6 expression comprises an oligonucleotide, an antisense oligonucleotide, a DNA oligonucleotide, an RNA oligonucleotide, an RNA oligonucleotide having at least a portion of said RNA oligonucleotide capable of hybridizing with RNA to form an oligonucleotide-RNA duplex, or a chimeric oligonucleotide.
29. A diagnostic method for identifying a disease state comprising identifying the presence of STAT 6 in a sample using at least one of the primers comprising SEQ ID NOs: 5 or 6, or the probe comprising SEQ ID NO: 7.
30. A kit or assay device comprising the compound of claim 1.
31. A method of treating an animal having a disease or condition associated with STAT 6 comprising administering to the animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of STAT 6 is inhibited.
32. The method of claim 31 wherein the disease or condition is an autoimmune disorder.

SEQUENCE LISTING

<110> William R. Shanahan, Jr.
Susan M. Freier
Kenneth W. Dobie

<120> MODULATION OF STAT 6 EXPRESSION

<130> ISIS0025-500WO (PTS-0010WO)

<150> 10/317,391

<151> 2002-12-11

<160> 141

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctcctcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

gtgcgcgcga gcccgaatc

20

<210> 3

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 3

atgcattctg cccccaagga

20

<210> 4

<211> 3046

<212> DNA

<213> H. sapiens

<220>

<221> CDS

<222> (166)...(2709)

```

<400> 4
atcttatttt tcttttttggg ggtggtggtg gaagggggga ggtgctagca gggccagcct      60

tgaactcgct ggacagagct acagacctat ggggcctgga agtgcccgcct gagaaaggga      120

gaagacagca gaggggttgc cgaggcaacc tccaagtccc agatc atg tct ctg tgg      177
                               Met Ser Leu Trp
                               1

ggt ctg gtc tcc aag atg ccc cca gaa aaa gtg cag cgg ctc tat gtc      225
Gly Leu Val Ser Lys Met Pro Pro Glu Lys Val Gln Arg Leu Tyr Val
  5                               10                               15                               20

gac ttt ccc caa cac ctg cgg cat ctt ctg ggt gac tgg ctg gag agc      273
Asp Phe Pro Gln His Leu Arg His Leu Leu Gly Asp Trp Leu Glu Ser
                               25                               30                               35

cag ccc tgg gag ttc ctg gtc ggc tcc gac gcc ttc tgc tgc aac ttg      321
Gln Pro Trp Glu Phe Leu Val Gly Ser Asp Ala Phe Cys Cys Asn Leu
                               40                               45                               50

gct agt gcc cta ctt tca gac act gtc cag cac ctt cag gcc tcg gtg      369
Ala Ser Ala Leu Leu Ser Asp Thr Val Gln His Leu Gln Ala Ser Val
                               55                               60                               65

gga gag cag ggg gag ggg agc acc atc ttg caa cac atc agc acc ctt      417
Gly Glu Gln Gly Glu Gly Ser Thr Ile Leu Gln His Ile Ser Thr Leu
                               70                               75                               80

gag agc ata tat cag agg gac ccc ctg aag ctg gtg gcc act ttc aga      465
Glu Ser Ile Tyr Gln Arg Asp Pro Leu Lys Leu Val Ala Thr Phe Arg
                               85                               90                               95                               100

caa ata ctt caa gga gag aaa aaa gct gtt atg gaa cag ttc cgc cac      513
Gln Ile Leu Gln Gly Glu Lys Lys Ala Val Met Glu Gln Phe Arg His
                               105                               110                               115

ttg cca atg cct ttc cac tgg aag cag gaa gaa ctc aag ttt aag aca      561
Leu Pro Met Pro Phe His Trp Lys Gln Glu Glu Leu Lys Phe Lys Thr
                               120                               125                               130

ggc ttg cgg agg ctg cag cac cga gta ggg gag atc cac ctt ctc cga      609
Gly Leu Arg Arg Leu Gln His Arg Val Gly Glu Ile His Leu Leu Arg
                               135                               140                               145

gaa gcc ctg cag aag ggg gct gag gct ggc caa gtg tct ctg cac agc      657
Glu Ala Leu Gln Lys Gly Ala Glu Ala Gly Gln Val Ser Leu His Ser
                               150                               155                               160

ttg ata gaa act cct gct aat ggg act ggg cca agt gag gcc ctg gcc      705
Leu Ile Glu Thr Pro Ala Asn Gly Thr Gly Pro Ser Glu Ala Leu Ala
                               165                               170                               175                               180

atg cta ctg cag gag acc act gga gag cta gag gca gcc aaa gcc cta      753
Met Leu Leu Gln Glu Thr Thr Gly Glu Leu Glu Ala Ala Lys Ala Leu
                               185                               190                               195

```

gtg ctg aag agg atc cag att tgg aaa cgg cag cag cag ctg gca ggg Val Leu Lys Arg Ile Gln Ile Trp Lys Arg Gln Gln Gln Leu Ala Gly 200 205 210	801
aat ggc gca ccg ttt gag gag agc ctg gcc cca ctc cag gag agg tgt Asn Gly Ala Pro Phe Glu Glu Ser Leu Ala Pro Leu Gln Glu Arg Cys 215 220 225	849
gaa agc ctg gtg gac att tat tcc cag cta cag cag gag gta ggg gcg Glu Ser Leu Val Asp Ile Tyr Ser Gln Leu Gln Gln Glu Val Gly Ala 230 235 240	897
gct ggt ggg gag ctt gag ccc aag acc cgg gca tcg ctg act ggc cgg Ala Gly Gly Glu Leu Glu Pro Lys Thr Arg Ala Ser Leu Thr Gly Arg 245 250 255 260	945
ctg gat gaa gtc ctg aga acc ctc gtc acc agt tgc ttc ctg gtg gag Leu Asp Glu Val Leu Arg Thr Leu Val Thr Ser Cys Phe Leu Val Glu 265 270 275	993
aag cag ccc ccc cag gta ctg aag act cag acc aag ttc cag gct gga Lys Gln Pro Pro Gln Val Leu Lys Thr Gln Thr Lys Phe Gln Ala Gly 280 285 290	1041
gtt cga ttc ctg ttg ggc ttg agg ttc ctg ggg gcc cca gcc aag cct Val Arg Phe Leu Leu Gly Leu Arg Phe Leu Gly Ala Pro Ala Lys Pro 295 300 305	1089
ccg ctg gtc agg gcc gac atg gtg aca gag aag cag gcg cgg gag ctg Pro Leu Val Arg Ala Asp Met Val Thr Glu Lys Gln Ala Arg Glu Leu 310 315 320	1137
agt gtg cct cag ggt cct ggg gct gga gca gaa agc act gga gaa atc Ser Val Pro Gln Gly Pro Gly Ala Gly Ala Glu Ser Thr Gly Glu Ile 325 330 335 340	1185
atc aac aac act gtg ccc ttg gag aac agc att cct ggg aac tgc tgc Ile Asn Asn Thr Val Pro Leu Glu Asn Ser Ile Pro Gly Asn Cys Cys 345 350 355	1233
tct gcc ctg ttc aag aac ctg ctt ctc aag aag atc aag cgg tgt gag Ser Ala Leu Phe Lys Asn Leu Leu Leu Lys Lys Ile Lys Arg Cys Glu 360 365 370	1281
cgg aag ggc act gag tct gtc aca gag gag aag tgc gct gtg ctc ttc Arg Lys Gly Thr Glu Ser Val Thr Glu Glu Lys Cys Ala Val Leu Phe 375 380 385	1329
tct gcc agc ttc aca ctt ggc ccc ggc aaa ctc ccc atc cag ctc cag Ser Ala Ser Phe Thr Leu Gly Pro Gly Lys Leu Pro Ile Gln Leu Gln 390 395 400	1377
gcc ctg tct ctg ccc ctg gtg gtc atc gtc cat ggc aac caa gac aac Ala Leu Ser Leu Pro Leu Val Val Ile Val His Gly Asn Gln Asp Asn 405 410 415 420	1425
aat gcc aaa gcc act atc ctg tgg gac aat gcc ttc tct gag atg gac	1473

Asn	Ala	Lys	Ala	Thr	Ile	Leu	Trp	Asp	Asn	Ala	Phe	Ser	Glu	Met	Asp	
				425					430					435		
cgc	gtg	ccc	ttt	gtg	gtg	gct	gag	cgg	gtg	ccc	tgg	gag	aag	atg	tgt	1521
Arg	Val	Pro	Phe	Val	Val	Ala	Glu	Arg	Val	Pro	Trp	Glu	Lys	Met	Cys	
			440					445					450			
gaa	act	ctg	aac	ctg	aag	ttc	atg	gct	gag	gtg	ggg	acc	aac	cgg	ggg	1569
Glu	Thr	Leu	Asn	Leu	Lys	Phe	Met	Ala	Glu	Val	Gly	Thr	Asn	Arg	Gly	
		455					460					465				
ctg	ctc	cca	gag	cac	ttc	ctc	ttc	ctg	gcc	cag	aag	atc	ttc	aat	gac	1617
Leu	Leu	Pro	Glu	His	Phe	Leu	Phe	Leu	Ala	Gln	Lys	Ile	Phe	Asn	Asp	
	470					475					480					
aac	agc	ctc	agt	atg	gag	gcc	ttc	cag	cac	cgt	tct	gtg	tcc	tgg	tcg	1665
Asn	Ser	Leu	Ser	Met	Glu	Ala	Phe	Gln	His	Arg	Ser	Val	Ser	Trp	Ser	
485					490				495						500	
cag	ttc	aac	aag	gag	atc	ctg	ctg	ggc	cgt	ggc	ttc	acc	ttt	tgg	cag	1713
Gln	Phe	Asn	Lys	Glu	Ile	Leu	Leu	Gly	Arg	Gly	Phe	Thr	Phe	Trp	Gln	
			505					510						515		
tgg	ttt	gat	ggt	gtc	ctg	gac	ctc	acc	aaa	cgc	tgt	ctc	cgg	agc	tac	1761
Trp	Phe	Asp	Gly	Val	Leu	Asp	Leu	Thr	Lys	Arg	Cys	Leu	Arg	Ser	Tyr	
			520					525					530			
tgg	tct	gac	cgg	ctg	atc	att	ggc	ttc	atc	agc	aaa	cag	tac	gtt	act	1809
Trp	Ser	Asp	Arg	Leu	Ile	Ile	Gly	Phe	Ile	Ser	Lys	Gln	Tyr	Val	Thr	
		535					540					545				
agc	ctt	ctt	ctc	aat	gag	ccc	gac	gga	acc	ttt	ctc	ctc	cgc	ttc	agc	1857
Ser	Leu	Leu	Leu	Asn	Glu	Pro	Asp	Gly	Thr	Phe	Leu	Leu	Arg	Phe	Ser	
	550					555					560					
gac	tca	gag	att	ggg	ggc	atc	acc	att	gcc	cat	gtc	atc	cgg	ggc	cag	1905
Asp	Ser	Glu	Ile	Gly	Gly	Ile	Thr	Ile	Ala	His	Val	Ile	Arg	Gly	Gln	
565				570				575						580		
gat	ggc	tct	cca	cag	ata	gag	aac	atc	cag	cca	ttc	tct	gcc	aaa	gac	1953
Asp	Gly	Ser	Pro	Gln	Ile	Glu	Asn	Ile	Gln	Pro	Phe	Ser	Ala	Lys	Asp	
				585				590						595		
ctg	tcc	att	cgc	tca	ctg	ggg	gac	cga	atc	cgg	gat	ctt	gct	cag	ctc	2001
Leu	Ser	Ile	Arg	Ser	Leu	Gly	Asp	Arg	Ile	Arg	Asp	Leu	Ala	Gln	Leu	
			600					605					610			
aaa	aat	ctc	tat	ccc	aag	aag	ccc	aag	gat	gag	gct	ttc	cgg	agc	cac	2049
Lys	Asn	Leu	Tyr	Pro	Lys	Lys	Pro	Lys	Asp	Glu	Ala	Phe	Arg	Ser	His	
		615					620					625				
tac	aag	cct	gaa	cag	atg	ggt	aag	gat	ggc	agg	ggt	tat	gtc	cca	gct	2097
Tyr	Lys	Pro	Glu	Gln	Met	Gly	Lys	Asp	Gly	Arg	Gly	Tyr	Val	Pro	Ala	
	630					635					640					
acc	atc	aag	atg	acc	gtg	gaa	agg	gac	caa	cca	ctt	cct	acc	cca	gag	2145
Thr	Ile	Lys	Met	Thr	Val	Glu	Arg	Asp	Gln	Pro	Leu	Pro	Thr	Pro	Glu	

645	650	655	660	
ctc cag atg cct acc atg gtg cct tct tat gac ctt gga atg gcc cct				2193
Leu Gln Met Pro Thr Met Val Pro Ser Tyr Asp Leu Gly Met Ala Pro	665	670	675	
gat tcc tcc atg agc atg cag ctt ggc cca gat atg gtg ccc cag gtg				2241
Asp Ser Ser Met Ser Met Gln Leu Gly Pro Asp Met Val Pro Gln Val	680	685	690	
tac cca cca cac tct cac tcc atc ccc ccg tat caa ggc ctc tcc cca				2289
Tyr Pro Pro His Ser His Ser Ile Pro Pro Tyr Gln Gly Leu Ser Pro	695	700	705	
gaa gaa tca gtc aac gtg ttg tca gcc ttc cag gag cct cac ctg cag				2337
Glu Glu Ser Val Asn Val Leu Ser Ala Phe Gln Glu Pro His Leu Gln	710	715	720	
atg ccc ccc agc ctg ggc cag atg agc ctg ccc ttt gac cag cct cac				2385
Met Pro Pro Ser Leu Gly Gln Met Ser Leu Pro Phe Asp Gln Pro His	725	730	735	740
ccc cag ggc ctg ctg ccg tgc cag cct cag gag cat gct gtg tcc agc				2433
Pro Gln Gly Leu Leu Pro Cys Gln Pro Gln Glu His Ala Val Ser Ser	745	750	755	
cct gac ccc ctg ctc tgc tca gat gtg acc atg gtg gaa gac agc tgc				2481
Pro Asp Pro Leu Leu Cys Ser Asp Val Thr Met Val Glu Asp Ser Cys	760	765	770	
ctg agc cag cca gtg aca gcg ttt cct cag ggc act tgg att ggt gaa				2529
Leu Ser Gln Pro Val Thr Ala Phe Pro Gln Gly Thr Trp Ile Gly Glu	775	780	785	
gac ata ttc cct cct ctg ctg cct ccc act gaa cag gac ctc act aag				2577
Asp Ile Phe Pro Pro Leu Leu Pro Pro Thr Glu Gln Asp Leu Thr Lys	790	795	800	
ctt ctc ctg gag ggg caa ggg gag tgc ggg gga ggg tcc ttg ggg gca				2625
Leu Leu Leu Glu Gly Gln Gly Glu Ser Gly Gly Gly Ser Leu Gly Ala	805	810	815	820
cag ccc ctc ctg cag ccc tcc cac tat ggg caa tct ggg atc tca atg				2673
Gln Pro Leu Leu Gln Pro Ser His Tyr Gly Gln Ser Gly Ile Ser Met	825	830	835	
tcc cac atg gac cta agg gcc aac ccc agt tgg tga tcccagctgg				2719
Ser His Met Asp Leu Arg Ala Asn Pro Ser Trp	840	845		
agggagaacc caaagagaca gctcttctac taccgccaca gacctgctct ggacacttgc				2779
tcatgccctg ccaagcagca gatggggagg gtgccctcct atccccacct actcctgggt				2839
caggaggaaa agactaacag gagaatgcac agtgggtgga gccaatccac tccttccctt				2899
ctatcattcc cctgccccacc tccttcagc actgactgga agggaagtgc aggcctctgag				2959

acacgccccca acatgcctgc acctgcagcg cgcacacgca cgcacacaca catacagagc 3019

tctctgaggg tgatggggct gagcagg 3046

<210> 5

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5

ccaaacgctg tctccgga 18

<210> 6

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 6

gctagtaacg tactgtttgc tgatgaa 27

<210> 7

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 7

ctactggtct gaccggctga tcattgg 27

<210> 8

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8

gaaggtgaag gtcggagtc 19

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

```

<400> 9
gaagatggtg atgggatttc
20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Probe

<400> 10
caagcttccc gttctcagcc
20

<210> 11
<211> 3971
<212> DNA
<213> H. sapiens

<220>
<221> CDS
<222> (281) ... (2320)

<400> 11
ggcacgaggc cggaacagc gggctggggc agccactgct tacactgaag agggaggacg 60
ggagaggagt gtgtgtgtgt gtgtgtgtgt gtgtgtgtat gtatgtgtgt gctttatctt 120
atTTTTcttt ttggtggtgg tggtggaagg ggggaggtgc tagcagggcc agccttgaac 180
tcgctggaca gagctacaga cctatggggc ctggaagtgc ccgctgagaa agggagaaga 240
cagcagaggg gttgccgagg caacctcaa gtcccagatc atg tct ctg tgg ggt 295
Met Ser Leu Trp Gly
1 5

ctg gtc tcc aag atg ccc cca gaa aaa gtg cag cgg ctc tat gtc gac 343
Leu Val Ser Lys Met Pro Pro Glu Lys Val Gln Arg Leu Tyr Val Asp
10 15 20

ttt ccc caa cac ctg cgg cat ctt ctg ggt gac tgg ctg gag agc cag 391
Phe Pro Gln His Leu Arg His Leu Leu Gly Asp Trp Leu Glu Ser Gln
25 30 35

ccc tgg gag ttc ctg gtc ggc tcc gac gcc ttc tgc tgc aac ttg gct 439
Pro Trp Glu Phe Leu Val Gly Ser Asp Ala Phe Cys Cys Asn Leu Ala
40 45 50

agt gcc cta ctt tca gac act gtc cag cac ctt cag gcc tcg gtg gga 487
Ser Ala Leu Leu Ser Asp Thr Val Gln His Leu Gln Ala Ser Val Gly
55 60 65

gag cag ggg gag ggg agc acc atc ttg caa cac atc agc acc ctt gag 535
Glu Gln Gly Glu Gly Ser Thr Ile Leu Gln His Ile Ser Thr Leu Glu
70 75 80 85

agc ata tat cag agg gac ccc ctg aag ctg gtg gcc act ttc aga caa 583

```

Ser	Ile	Tyr	Gln	Arg	Asp	Pro	Leu	Lys	Leu	Val	Ala	Thr	Phe	Arg	Gln		
				90					95					100			
ata	ctt	caa	gga	gag	aaa	aaa	gct	gtt	atg	gaa	cag	ttc	cgc	cac	ttg	631	
Ile	Leu	Gln	Gly	Glu	Lys	Lys	Ala	Val	Met	Glu	Gln	Phe	Arg	His	Leu		
			105					110					115				
cca	atg	cct	ttc	cac	tgg	aag	cag	gaa	gaa	ctc	aag	ttt	aag	aca	ggc	679	
Pro	Met	Pro	Phe	His	Trp	Lys	Gln	Glu	Glu	Leu	Lys	Phe	Lys	Thr	Gly		
		120					125					130					
ttg	cgg	agg	ctg	cag	cac	cga	gta	ggg	gag	atc	cac	ctt	ctc	cga	gaa	727	
Leu	Arg	Arg	Leu	Gln	His	Arg	Val	Gly	Glu	Ile	His	Leu	Leu	Arg	Glu		
	135					140					145						
gcc	ctg	cag	aag	ggg	gct	gag	gct	ggc	caa	gtg	tct	ctg	cac	agc	ttg	775	
Ala	Leu	Gln	Lys	Gly	Ala	Glu	Ala	Gly	Gln	Val	Ser	Leu	His	Ser	Leu		
150					155				160						165		
ata	gaa	act	cct	gct	aat	ggg	act	ggg	cca	agt	gag	gcc	ctg	gcc	atg	823	
Ile	Glu	Thr	Pro	Ala	Asn	Gly	Thr	Gly	Pro	Ser	Glu	Ala	Leu	Ala	Met		
				170					175					180			
cta	ctg	cag	gag	acc	act	gga	gag	cta	gag	gca	gcc	aaa	gcc	cta	gtg	871	
Leu	Leu	Gln	Glu	Thr	Thr	Gly	Glu	Leu	Glu	Ala	Ala	Lys	Ala	Leu	Val		
			185					190					195				
ctg	aag	agg	atc	cag	att	tgg	aaa	cgg	cag	cag	cag	ctg	gca	ggg	aat	919	
Leu	Lys	Arg	Ile	Gln	Ile	Trp	Lys	Arg	Gln	Gln	Gln	Leu	Ala	Gly	Asn		
		200					205					210					
ggc	gca	ccg	ttt	gag	gag	agc	ctg	gcc	cca	ctc	cag	gag	agg	tgt	gaa	967	
Gly	Ala	Pro	Phe	Glu	Glu	Ser	Leu	Ala	Pro	Leu	Gln	Glu	Arg	Cys	Glu		
	215					220					225						
agc	ctg	gtg	gac	att	tat	tcc	cag	cta	cag	cag	gag	gta	ggg	gcg	gct	1015	
Ser	Leu	Val	Asp	Ile	Tyr	Ser	Gln	Leu	Gln	Gln	Glu	Val	Gly	Ala	Ala		
230					235					240					245		
ggt	ggg	gag	ctt	gag	ccc	aag	acc	cgg	gca	tcg	ctg	act	ggc	cgg	ctg	1063	
Gly	Gly	Glu	Leu	Glu	Pro	Lys	Thr	Arg	Ala	Ser	Leu	Thr	Gly	Arg	Leu		
			250					255						260			
gat	gaa	gtc	ctg	aga	acc	ctc	gtc	acc	agt	tgc	ttc	ctg	gtg	gag	aag	1111	
Asp	Glu	Val	Leu	Arg	Thr	Leu	Val	Thr	Ser	Cys	Phe	Leu	Val	Glu	Lys		
			265					270					275				
cag	ccc	ccc	cag	gta	ctg	aag	act	cag	acc	aag	ttc	cag	gct	gga	gtt	1159	
Gln	Pro	Pro	Gln	Val	Leu	Lys	Thr	Gln	Thr	Lys	Phe	Gln	Ala	Gly	Val		
		280					285					290					
cga	ttc	ctg	ttg	ggc	ttg	agg	ttc	ctg	ggg	gcc	cca	gcc	aag	cct	ccg	1207	
Arg	Phe	Leu	Leu	Gly	Leu	Arg	Phe	Leu	Gly	Ala	Pro	Ala	Lys	Pro	Pro		
	295					300					305						
ctg	gtc	agg	gcc	gac	atg	gtg	aca	gag	aag	cag	gcg	cgg	gag	ctg	agt	1255	
Leu	Val	Arg	Ala	Asp	Met	Val	Thr	Glu	Lys	Gln	Ala	Arg	Glu	Leu	Ser		

310	315	320	325	
gtg cct cag ggt cct ggg gct gga gca gaa agc act gga gaa atc atc				1303
Val Pro Gln Gly Pro Gly Ala Gly Ala Glu Ser Thr Gly Glu Ile Ile	330	335	340	
aac aac act gtg ccc ttg gag aac agc att cct ggg aac tgc tgc tct				1351
Asn Asn Thr Val Pro Leu Glu Asn Ser Ile Pro Gly Asn Cys Cys Ser	345	350	355	
gcc ctg ttc aag aac ctg ctt ctc aag aag atc aag cgg tgt gag cgg				1399
Ala Leu Phe Lys Asn Leu Leu Leu Lys Lys Ile Lys Arg Cys Glu Arg	360	365	370	
aag ggc act gag tct gtc aca gag gag aag tgc gct gtg ctc ttc tct				1447
Lys Gly Thr Glu Ser Val Thr Glu Glu Lys Cys Ala Val Leu Phe Ser	375	380	385	
gcc agc ttc aca ctt ggc ccc ggc aaa ctc ccc atc cag ctc cag gcc				1495
Ala Ser Phe Thr Leu Gly Pro Gly Lys Leu Pro Ile Gln Leu Gln Ala	390	395	400	405
ctg tct ctg ccc ctg gtg gtc atc gtc cat ggc aac caa gac aac aat				1543
Leu Ser Leu Pro Leu Val Val Ile Val His Gly Asn Gln Asp Asn Asn	410	415	420	
gcc aaa gcc act atc ctg tgg tac aat gcc ttc tct gag atg gac cgc				1591
Ala Lys Ala Thr Ile Leu Trp Tyr Asn Ala Phe Ser Glu Met Asp Arg	425	430	435	
gtg ccc ttt gtg gtg gct gag cgg gtg ccc tgg gag aag atg tgt gaa				1639
Val Pro Phe Val Val Ala Glu Arg Val Pro Trp Glu Lys Met Cys Glu	440	445	450	
act ctg aac ctg aag ttc atg gct gag gtg ggg acc aac cgg ggg ctg				1687
Thr Leu Asn Leu Lys Phe Met Ala Glu Val Gly Thr Asn Arg Gly Leu	455	460	465	
ctc cca gag cac ttc ctc ttc ctg gcc cag aag atc ttc aat gac aac				1735
Leu Pro Glu His Phe Leu Phe Leu Ala Gln Lys Ile Phe Asn Asp Asn	470	475	480	485
agc ctc agt atg gag gcc ttc cag cac cgt tct gtg tcc tgg tcg cag				1783
Ser Leu Ser Met Glu Ala Phe Gln His Arg Ser Val Ser Trp Ser Gln	490	495	500	
ttc aac aag gag atc ctg ctg ggc cgt ggc ttc acc ttt tgg cag tgg				1831
Phe Asn Lys Glu Ile Leu Leu Gly Arg Gly Phe Thr Phe Trp Gln Trp	505	510	515	
ttt gat ggt gtc ctg gac ctc acc aaa cgc tgt ctc cgg agc tac tgg				1879
Phe Asp Gly Val Leu Asp Leu Thr Lys Arg Cys Leu Arg Ser Tyr Trp	520	525	530	
tct gac cgg ctg atc att ggc ttc atc agc aaa cag tac gtt act agc				1927
Ser Asp Arg Leu Ile Ile Gly Phe Ile Ser Lys Gln Tyr Val Thr Ser	535	540	545	

ctt ctt ctc aat gag ccc gac gga acc ttt ctc ctc cgc ttc agc gac	1975
Leu Leu Leu Asn Glu Pro Asp Gly Thr Phe Leu Leu Arg Phe Ser Asp	
550 555 560 565	
tca gag att ggg ggc atc acc att gcc cat gtc atc cgg ggc cag gat	2023
Ser Glu Ile Gly Gly Ile Thr Ile Ala His Val Ile Arg Gly Gln Asp	
570 575 580	
ggc tct cca cag ata gag aac atc cag cca ttc tct gcc aaa gac ctg	2071
Gly Ser Pro Gln Ile Glu Asn Ile Gln Pro Phe Ser Ala Lys Asp Leu	
585 590 595	
tcc att cgc tca ctg ggg gac cga atc cgg gat ctt gct cag ctc aaa	2119
Ser Ile Arg Ser Leu Gly Asp Arg Ile Arg Asp Leu Ala Gln Leu Lys	
600 605 610	
aat ctc tat ccc aag aag ccc aag gat gag gct ttc cgg agc cac tac	2167
Asn Leu Tyr Pro Lys Lys Pro Lys Asp Glu Ala Phe Arg Ser His Tyr	
615 620 625	
aag cct gaa cag atg ggt aag gat ggc agg ggt tat gtc cca gct acc	2215
Lys Pro Glu Gln Met Gly Lys Asp Gly Arg Gly Tyr Val Pro Ala Thr	
630 635 640 645	
atc aag atg acc gtg gaa agg gac caa cca ctt cct acc cca gag ctc	2263
Ile Lys Met Thr Val Glu Arg Asp Gln Pro Leu Pro Thr Pro Glu Leu	
650 655 660	
cag atg cct acc atg gtg cct tct tat gac ctt gga atg gcc ctg att	2311
Gln Met Pro Thr Met Val Pro Ser Tyr Asp Leu Gly Met Ala Leu Ile	
665 670 675	
cct cca tga gcatgcagct tggcccagat atgggtgcccc aggtgtaccc accacactct	2370
Pro Pro	
cactccatcc ccccgatatca aggcctctcc ccagaagaat cagtcaacgt gttgtcagcc	2430
ttccaggagc ctcacctgca gatgcccccc agcctgggcc agatgagcct gccctttgac	2490
cagcctcacc ccaggggcct gctgccgtgc cagcctcagg agcatgctgt gtccagccct	2550
gacccctgc tctgctcaga tgtgaccatg gtggaagaca gctgcctgag ccagccagtg	2610
acagcgtttc ctcagggcac ttggattggg gaagacatat tccctcctct gctgcctccc	2670
actgaacagg acctactaa gcttctcctg gaggggcaag gggagtcggg gggaggggtcc	2730
ttgggggcac agcccctcct gcagccctcc cactatgggc aatctgggat ctcaatgtcc	2790
cacatggacc taagggccaa cccagttgg tgatcccagc tggagggaga acccaaagag	2850
acagctcttc tactaccccc acagacctgc tctggacact tgctcatgcc ctgccaagca	2910
gcagatgggg aggggtgccct cctatcccca cctactcctg ggtcaggagg aaaagactaa	2970
caggagaatg cacagtgggt ggagccaatc cactccttcc tttctatcat tcccctgccc	3030

```

acctccttcc agcactgact ggaagggaag ttcaggctct gagacacgcc ccaacatgcc 3090
tgcacctgca gcgcgcacac gcacgcacac acacatacag agctctctga gggatgatggg 3150
gctgagcagg agggggggctg ggtaagagca cagggttaggg catggaaggc ttctccgccc 3210
attctgaccc agggcctagg acggataggc aggaacatac agacacatth acactagagg 3270
ccagggatag aggatattgg gtctcagccc taggggaatg ggaagcagct caagggaccc 3330
tgggtgggag cataggaggg gtctggacat gtgggtacta gtacaggtht tgccctgatt 3390
aaaaaatctc ccaaagcccc aaattcctgt tagccagggt gaggtctctg atacgtgtat 3450
gagactatgc aaaagtacaa gggctgagat tcttcgtgta tagctgtgtg aacgtgtatg 3510
tacctaggat atgttaaag tatagctggc accttagttg catgaccaca tagaacatgt 3570
gtctatctgc ttttgccctac gtgacaacac aaatttgga gggtgagaca ctgcacagaa 3630
gacagcagca agtgtgctgg cctctctgac atatgctaac ccccaaatac tctgaatttg 3690
gagtctgact gtgccaagt gggccaagt ggctgtgaca tctacgtatg gctccacacc 3750
tccaatgctg cctgggagcc agggtgagag tctgggtcca ggcctggcca tgtggccctc 3810
cagtgtatga gagggccctg cctgctgcat cttttctgtt gcccaccca cgcagcctt 3870
cccttctctc ccctatccca ttctccctct caaggcaggg gtcatagatc ctaagccata 3930
aaataaatth tattccaaaa taiaaaaaaa aiaaaaaaaa a 3971

```

<210> 12

<211> 16500

<212> DNA

<213> H. sapiens

<220>

<400> 12

```

tcccccaag cctgggtcca aggcctggac ccagtcctg atccccacg tgttccccca 60
ctcggcacag gaggcacaca tattcaccac actttcttcc tottctctct ccagcccact 120
ttctcttctc tgtgtcgtca gagctccagg gagggacctg ggtagaagga gaagccggaa 180
acagcgggct ggggcagcca ctgcttacac tgaagaggga ggacgggaga ggagtgtgtg 240
tgtgtgtgtg tgtgtgtgta tgtatgtgtg tgctttatct tatttttctt ttggtggtg 300
gtgggtggaag gggggagggt ctagcagggc cagccttgaa ctgctggac agagctacag 360
acctatgggg cctggaagtg cccgctgaga aagggagaag acagcagagg ggttgccgag 420
gtgaggggtt gcctccgagg tgggtgcggg ggcctctatg agtgcattgg ggtggattcg 480

```

tgggggggagc	tctcgggatac	ctccccctggc	tgggtggatg	gtccccaaga	gatggtttca	540
gctagtgttg	gtggctgggtg	gcactgggtt	ttagcagttt	cgaactcctg	gaggaatctg	600
ggaggggtcca	ggcctcagta	ctccccctccc	ccatgggtca	cgttttcaca	gcctcacccc	660
tgcacccccca	gggccatgga	aagtcaggga	aaggagggtga	aggagtgcc	ctctgcctg	720
agtcgggggga	agtggccgcc	cctccctgga	aggttgatgc	cagagggcag	tggatccttg	780
ttaaaccct	atcctgccct	ccactaaagg	ttcctgttca	aggggtgtggc	tggggcgtga	840
gcaagcccca	gatgtagacc	tcatgggtggc	ccagacgagg	gggaatttcc	ccctcaaaac	900
tgctccacgc	ttggctgctg	tagacgctga	gatttcccag	cgcgggcgcc	gagttaacct	960
tcctcgtgct	gaactggctc	cacctccccg	cctgccccca	ccgccacatt	cacgcattgg	1020
gcaactcaga	gaagctgttt	taactttcga	tcctgtggtc	ccacaatcag	aggactcggg	1080
cagatagggg	ttgagataag	cgagtttagg	ccaccaagcg	ggcggacgag	gatcccagac	1140
cttgcgcttc	ccttctgagt	ttggggaggta	acactggccc	cgccccctcac	gccgtggctc	1200
ctccctccct	tccccttcaa	ggggctgaag	acaaaagggtg	cccctgtcct	ggtcaagcca	1260
atcgaccag	ccttggttatg	ggttgggggtg	gggagaaatg	tgtcctcctg	atggctgggg	1320
aagaagaggg	gttgatatt	tctagccagg	gccatgccag	gaggctggtc	actctgcaag	1380
gggatgcaga	ggaaagcgg	gcccactcac	tccagaggac	ctttctctct	tgggctagag	1440
aaaggcctat	tggaggaacc	tgagcaggag	gggtaaggat	tctgccttga	ggagaaaaga	1500
gctggggtaa	gtgggcactg	gaggaaagag	gggcatgaag	gtcttgagc	agaaacatcc	1560
agagaaggga	cctctccatt	ttccatccct	ctgagaggcc	tgggagagg	gagaggctga	1620
acgtgcaaca	ggaggacttg	gggttactgg	gtttggggag	acctggggag	ttgtcatccc	1680
atcctctccc	tcatctctgg	gagagggata	ttatgagaaa	cgtgaactga	gaggccccctg	1740
ggaaaccact	ggttaccag	tcctccctga	acctggaaat	ggggatgcaa	ccccctcttc	1800
tacttccctg	tcccctcctc	tcctttctac	ctgttttctg	ctctcatctt	tgccctctag	1860
ccctccagct	tcctctctct	tctaggctct	ttcctcctag	cttaactaac	ccgccttttt	1920
tccagtctct	tccatcctct	tccttagttc	tctctacttt	ccttttccac	ctctcctcct	1980
tcaagtctcc	tcccaccttc	ccccacttct	taggatgata	agatttgccc	ctggaaggga	2040
tcctaacaac	acagtgcgat	ggttaatccc	cactcagatt	caaagcctgc	tttccaaact	2100
cacttactga	gtggccttgg	gcagagtaga	gaaactcctt	aagcctcagt	ttcttcatct	2160
ataaaatggg	atattatata	ttttaaaaag	tgtcgtgagg	cctgaaggag	ataatacact	2220

gagtgtaatg cctcatacac agtaagtgct taacaaatag tagctgttat tactctccca 2280
 tcctcttcat catctagcct tgtggttttc atttttattt tatttcattt atttatttat 2340
 ttattttgag acagagtctc tctctgtcgc ccaggctgga gtgcagtggc tcgatctctg 2400
 ctactgcaa gctccgcccc ccaggttcac gccattctgt cacctcagcc tcccagtag 2460
 ctgggactac aggcgtcgc caccacgccc tgctaatttt gtttttgtat ttttagtaga 2520
 gatggggttt cactgtgtta gccaggatgg tcttgatctc ctgacctcgt gatctgcccg 2580
 cctcggcctc ccaaagcgtt gggattacag gcatgagcca ctgcgcctgg ccgagccttg 2640
 tggttttcaa attatctcat ggagtcctag aattttgaga ggtttgtcta gggatgcctt 2700
 tggcgtcagg aggtggggag agggaagtag aagcagtoga gtttcaggct ttccatgctt 2760
 gctttcaaca gggcatcttc ggtttcgtac cttttatgta attgagattc cacagattaa 2820
 aagctgacat tgcctaccgc tttaaaaagt ttggaaagtt ttccactcat ctaacactca 2880
 tattttatag atgagaagat cgaagccac aaagggaagg ctctttgccc acagaaccag 2940
 agccaggctt agagctgcaa ctaaactctc tgccactcta agagagctct cgctctactg 3000
 ccctgtctcc ctttgctcc ccatccctct ggtacagct cagctcttcc caccctgtg 3060
 tctatcactg aaggagttac ccccatctca ggcattgact caggatgccc ctggtttaag 3120
 gtggctctggc catgagtggg ggtggggaca gtccctagga gggctatcta tgggaggtcc 3180
 ctggctgccc caggagatag gccaaagttc ttgggcaccc ctgagagtgg ccttattttt 3240
 ctctccagg caacctcaa gtcccagatc atgtctctgt ggggtctggg ctccaagatg 3300
 cccccagaaa aagtgcagcg gctctatgtc gactttcccc aacacctgcg gcattctctg 3360
 ggtgactggc tggagagcca gccctggtga gtccctggctg ctccctgctg gtccccaag 3420
 tcttccctaa ctcatcttcc ttctccttag atttttctcc cctcaccat ggattcagaa 3480
 cttgagacct gttattccat gtgtagtgac ctagatttag caggagctct gtgccccatc 3540
 aagaccaggc tatgaatgtt gacagatgga gaccccatct cttaggaggc tgagccgaag 3600
 aggagggggg tttgggctgg gacaaaggca cttctcataa cagctagaag actgggaaac 3660
 aaggcgcatt ggtgaaagct acagagggcc tagatggaga ataaggagcg agaaaggaaac 3720
 tgctgagctt ttggctgtgg ggtaaagggt caggagagct gaggaagccc tggcctgagg 3780
 tagcctcatc ctgatcttcc tgcaggaggt tcctggctcg ctccgacgcc ttctgtgca 3840
 acttggttag tgccctactt tcagacactg tccagcacct tcaggcctcg gtgggagagc 3900

aggggggaggg gagcaccatc ttgcaacaca tcagcaccct tgaggtgggg caggagggga 3960
 ggggacaagg ctgggtgggg ctgaggttga actgggttga gcattggggc ctggaagaaa 4020
 attggttggga tgctggaagc aaattggtgt tcctgtggtt aactgctagc tagcaggcaa 4080
 attagatttt aaaagcatgc aaatgcacaa aaacttctgg agtctacagt tgtgcttcct 4140
 tatagtatat gtgtgaatgc aggctgggg attggaggga ttgaaggaca tgggtaagag 4200
 caaagctcac tgtttaccac cctcatttct gtagagcata tatcagaggg acccctgaa 4260
 gctggtggcc actttcagac aaatacttca aggagagaaa aaagctgtta tggaacaggt 4320
 attgtgatat tccacctccc accccaactc aatcccctga gactttggcc tgagccatga 4380
 caaactagaa agaatttgaa cctcagtaaa ggctcagtgt tctaggcca ggaatgacca 4440
 aaggaggttc ctagggtcag agtgaacccc aagtcaagct cagggaatct ttctatgagg 4500
 gactgaaggt aagaggccgg ggagaacaga gcaagggata aggagctgat tctgctagga 4560
 gcaaggtctt atctccacga tattccaaaa ggtcaggaag aactgccaaa ggggagaggg 4620
 gaacaagaaa acgctatctg cagagcagag agtggaggcc aggtatagag ggatgagcag 4680
 agtgtttcac ttcttggcat ctgtccttcc tgtgtagttc cgccacttgc caatgccttt 4740
 ccaactggaag caggaagaac tcaagtttaa gacaggcttg cggaggctgc agcaccgagt 4800
 aggggagatc caccttctcc gagaagccct gcagaagggg gctgaggctg gccaagggtg 4860
 gggccagggt gggtcttggg agtgtgtagg agtggttgcc tcttggtatct caaccttctc 4920
 tgaacctota atctgtctgc acccttgatt tctgccccca accctcagt tctctgcaca 4980
 gcttgataga aactcctgct aatgggactg ggccaagtga ggtgagtaat gggctgacag 5040
 gtggagacct tgggtcaaagt gcagctggag ggatggaagc tagacctcag aaagacacag 5100
 gctgaagtag ggcaaggga tgccagagga gtgagaaaa gagccgtatc ccaggagctg 5160
 ggtgtggagg cagcgtgagg ccctggctca gggccctctc tgcccatagg ccctggccat 5220
 gctactgcag gagaccactg gagagctaga ggcagccaaa gccctagtgc tgaagaggat 5280
 ccagatttgg aaacggcagc agcagctggc agggaatggc gcaccgtttg aggagagcct 5340
 ggccccactc caggagaggt tgggctaggg ctgatgggga agagggggca agctgggggt 5400
 gggcagctga ccctgctgaa ggccctacag gtgagagaaa gaagccaggc gggagggcct 5460
 tggagtggac caagatgcat aaaagccagt tccagcgggg ctgtgcacac tgtcgttcag 5520
 gtgcacatct gtacaagtgg gcctagtggg ggggcacaag cggggactca tccaaccag 5580
 gcttctctcc tcaagcccca tgcctagagg aataggaggg cttttccatt tggtttattg 5640

ggtgggaaca ctttccaatt tgccacaaag cactgtaagt ggtggcagtt gtccctgggtg 5700
 caagagccgt cgggggagag gcagctgggt ttccacaggg ggtgtaggca ctgagaatga 5760
 acctcccacc cagaccctag gccaacagat cacagaaccc ccttcagccc aggtgccttg 5820
 cagccacacc cactaccac cccacttctc cacacatgat agcctttctc cctgggtata 5880
 ggggaagggg gtctgggccg gagcaagcag ccttaatcct gtgccccctg accactgtcc 5940
 tggccccagg tgtgaaagcc tgggtggacat ttattcccag ctacagcagg aggtaggggc 6000
 ggctggtggg gagcttgagc ccaagaccog ggcatogctg actggccggc tggatgaagt 6060
 cctgagaacc ctcgtcacca ggtattcccc gggagctccc agtctggcct agaacagacc 6120
 tcgggaagaa aagaaggggg ctagagctgt ggggagggca ccagcaggga cctagcccc 6180
 aactcccctt gtgtccctct cactcccagt tgcttcctgg tggagaagca gccccccag 6240
 gtactgaaga ctgagaccaa gttccaggct ggagttcgat tcctgttggg cttgagggtc 6300
 ctggggggccc cagccaagcc tccgctggtc agggccgaca tgggtgacaga gaagcaggcg 6360
 cgggagctga gtgtgcctca ggtcctggg gctggagcgt aagctgggat tggacctggg 6420
 gttggagaag ggctgttagg gtgatggagg cagcctggag ggctggcact gaaaagagca 6480
 agggatgggg agggagggcc atgggatgtg gagaccctga atggtcaagg cagaggaaag 6540
 ggagggaccc atttagggct ggaatggggg gggggcatca tgatttggcc aagatgggga 6600
 ctctccctt aagaacccaa acagagacat ggagatttag ggctgggtgac agtgggtagt 6660
 ctacactcac ccatgcactc gccacacctg acgacagtga gatgagctcg ttcacactct 6720
 gacctcccct ggcagagaaa gcaactggaga aatcatcaac aacactgtgc ccttggagaa 6780
 cagcattcct gggaactgct gctctgccct gttcaagaac ctgggtgaggg gctttgggg 6840
 gcagtgaggg gggcaccact aggagactgt gggactctcc ttggagagga tgtcaggaag 6900
 cccaggagga gcggtctctg tcctcatgac ctgcaccttg ctctccctca cccacccac 6960
 agcttctcaa gaagatcaag cgggtgtgagc ggaagggcac tgagtctgtc acagaggaga 7020
 agtgcgctgt gctcttctct gccagcttca cacttggccc cggcaaactc cccatccagc 7080
 tccaggtgaa ccgtggccca gccctgcccc aatctgggac cccgagtoct cctccaatgc 7140
 cacacacaag ggccctggac cctcacctct tgtgactgcc ccatacccca tgtgtctggg 7200
 attcatgcac actggggccc gggtagtggt gggtagcaa gagcatggag tgcacagggc 7260
 agggaatggt agtggatagc agcaaacact tcggaagcac ttctataga ccagggcact 7320

ctattaaatg atacatacgc acatgcgtgc cagcacacac acgtctgggtt ttcacaataa 7380
 cattatgagg taggcagtat tatcagcctc attttataga taaggacatt gagacagaga 7440
 gtttaagtag tttgtcccag tcacacagct aagtgttga gctggatattt gaaacctgga 7500
 ggtctgggtc catagcgatg actaataacc acttctctac ggtgaggccc tgattgagct 7560
 tcagaacgca tttaataaca tggcatgagc tttttgatta tgatgtgtga gtccaataac 7620
 ttctctgagt gctcagagcc agtcccctga ggaaacttct tgcttcaacta agaaaccct 7680
 gtccggctgg gcatggtggc tcaagcctgt aatcccagca ctttgggagg ccgaggtggg 7740
 tagatcaciaa ggtcaggagt tcaagaccag cctggccaat atggtgaaac ccgctctcca 7800
 ctaaaaatac aaaaattagc tgggcgtggg ggtgcaggcc tgtagtccca gctgctcggg 7860
 aggctaagca ggagaatcgc ttgaaccag gaggcggagg ttgcagtga ccaagattgc 7920
 gccactgccc ttcagcctgg gcgacagagc aagactatgt ctcaaaaaca aaacaaaaca 7980
 actcagcact ttgggaggcc aaggtaggag gatcgcttga gcctgcaagt ttaagaccag 8040
 cctgggctac ataggagat ccaatctcta caaaaaataa aaaattggcc gggcatggtg 8100
 gctcacgcct gtaatccag cactttggga ggccaaggcg ggcgatcat gaggtcagga 8160
 aatcgagacc atcctggcta acacggtgaa acctcgatc tactaaaaat acaaaaaatt 8220
 agccaggcat ggtggcgggc gcctgagtcc cagctactcg ggaggctgaa gcaggagaat 8280
 ggctgaacc tgggaggag agcttgagc gagccaagat cgcgcgctg cactccagcc 8340
 tgagtgaagc agcgagactc tgtctcaaaa ataaataaat aaataattag ctggattagg 8400
 tggtagattt ctgtagttcc agctattcag gaggtgagg tggaaggatc acttgagccc 8460
 tgaaggctga ggctgcagt agctgagatt gcactactgc actccagcct gggcaacaga 8520
 gtgagatact atctaaaaa aaaaaaaaaa aaaaaaagg aaagaaagaa agaaaagaaa 8580
 cccctgtcct caccctcttc aggccctgtc tctgcccctg gtggtcatcg tccatggcaa 8640
 ccaagacaac aatgccaaag ccactatcct gtgggacaat gccttctctg agatggtgag 8700
 gaaagtcctg gagttggagg gaacaggggc aggggtgggtt ctaacatggg cagtggtgca 8760
 ggctgctga tggggtgggt ggcatgttta aatgggtgtg accttaaac tttctcatgg 8820
 gcctgctttc gtgcttctga cctcttttca cccagtcctt aacaactatc aggccacagc 8880
 actgtaacct agaaaaaaca gcatgtttgt gagcgatata aggggctgtg gaggggtagg 8940
 ccacaggcag gtgggagggg tgaaggccgg ccgaggaat aacaagacgg tagcctgcag 9000
 tgctctcttc ttcccccttc tcccaggac cgcgtgccct ttgtgggtggc tgagcgggtg 9060

ccctgggaga agatgtgtga aactotgaac ctgaagttca tggctgaggt ggggaccaac 9120
 cgggggctgc tcccagagca cttcctcttc ctggcccaga agatcttcaa tgacaacagc 9180
 ctgagtatgg aggccttcca gcaccgttct gtgtcctggt cgcagttcaa caaggtcatt 9240
 ctctgcccct ttggacctcc ccccccaag ctcttcatcc ctggggcact cagggcctgc 9300
 tcagcctcca tgcagggacc ttccactgga ttctccacag tgccccctca ggtccttttag 9360
 gaaggcctgt catggaccag ggaggaaaaa cccaggcctt gggggttggc tctggagatg 9420
 cgttctctga catccctgag gttttgtctt gggggccatc tgtccttctt ctttaccagt 9480
 gacttgcatt actcaccag gttgtgtgta aacagagctc tgattcaaag tgactttgac 9540
 ctgttggaat aatagttcct ggccgggcac agcggctcat gcctgtaatc ccagtctttg 9600
 acatgccggg gtgggtggat cacctgaggt caggagtttg agaccagcct ggccaacatg 9660
 gtgaaactcc atctctacta aaaatacaaa aattagccag ttgcggtggc acatgcctgt 9720
 aatcccagct acatgggagg ctgacgcagg agaattgctt gaaccagga ggtggagggt 9780
 gcagtgagct gagatcatac cactgcactc aagcctgggt gacagagcaa gactctgtct 9840
 caaaaaaaaa aaaaaaaaaa ggccaggcat ggtggttcat gcctgtaatc ccagcacttt 9900
 gggaggccga gacggataga tcacctgagg tcaggagtcc gagaccagcc tggccaacat 9960
 ggcaaaacc cgtctctact aaaaacaaaa aatagccag gagtggctgt ttgcgtctgt 10020
 aatcccagct actcggtgga ggcaggaggt gaaccagga ggtagaggct gcagggaaga 10080
 tgaaaccatt gcactccagc ctgggcaaga ctctgtatca aaaaaaaaaa aaaaaaggc 10140
 taggtgtggt ggctcacacc tgtaatcca gcactttggg aggtgaggc gggcggtatca 10200
 caaggtaag agatcgagac catcctgacc aacatggtga aacccgtct ctactaaaaa 10260
 tacaaaaatt acctgggcat ggtggcgcat gcctgtagtc ccaactactc gggaggctga 10320
 ggcaggagaa tcacttgaac ctgggaggca gaggttcag cgagccaaga ttgtgccact 10380
 gcactccagc ctgccaacag aatgagattc tgtctaaaaa aaaaaagaaa gaaagaaaga 10440
 aagaaaaaga attcctgttg caaaaactga aaaaaatccc acagggacat gtgcagtaat 10500
 accagctacc acgtgttgac agcttatatg ccaggcgctg tgcttaacac cttatgtatg 10560
 ttatctcact taatcctccc aacatctctt tgaggtagat actattatta tccccatttt 10620
 acagatgagg aatctgatgc tcagagggtt atgtagtttg ttcaagttcc caaagcagg 10680
 gagtgccatg gctaggagag aaccacatat ttctgactct tgctctttta ttttatgtta 10740

tattatgtta ttttatgttt tgggtttttt ttcttttctt tctttctttc tttctttctt 10800
tctttctctt tctttctttc tttctttctt tctttctttc tttctttctt tctctttctc 10860
tttctctctt tttctttctt ttgtgtgaga cagaatcttt aaagagaaga aagaaatgct 10920
catgtgacca gaggggtgtgt tagctaaagg gagcaagaca gtcacacca gcaggttacc 10980
ttcctttggg cgtcacctct gccacacctc cttagggaga ggggtgtagca tagtagttaa 11040
gaggggctcc agggccagaa tgccctgggtt taaatcctag ctctgcctct taccagctat 11100
gtagacctgg gcaagtcatc cgacgttttt ggacttccat ttcttcatct gtaagatgga 11160
attattataa tccctacttc catagcctgg taaagagcaa ataaatatat ggaaaggctt 11220
gaaatagtgg ctggcacgtg taagcattag gattggctgt tgtcattgat ggagtctcag 11280
gttcggctctg atcctcagcc ctgtgattct gtcgtgaggg cactcacagc tccctgcctg 11340
ccctaaacag gctccagctc tggccctccc tgggtccaca cctttcccc tctcccccta 11400
ggagatcctg ctgggccgtg gcttcaoctt ttggcagtgg tttgatgggtg tccctggacct 11460
caccaaagc tgtctccgga gctactggtc tgaccgggtga gtccccaccc tgggtagtct 11520
gagcagccat acaccagtca cctccatact cactgcccac gccccatcct ctccttcac 11580
ccggccaggc tgatcattgg cttcatcagc aaacagtaag ttactagcct tcttctcaat 11640
gagcccagc gaacctttct cctccgttc agcgactcag agattggggg catcaccatt 11700
gcccattgca tccggggcca ggatgggtgag gccaccccag ccagtcctct gtctctgtgc 11760
ctgtgccctc tgggggtttt tctgggaatg aaatgtcctg accttctga tgccgatcct 11820
gatcttcagg aagttcttcc agcttctctt cttccttctg tgggtctaaat gttcaccttc 11880
tactgtgag ctctgtggga acggagacta gtgggtctct ctcctcagg agccccaccc 11940
taggtcctct ctccttgcc ttgggtggagt gagaacaggc cttatggtag ggggtgggga 12000
aggggaagaa agtccggaca gagggatctc agggctctct tccctaccata ggctctccac 12060
agatagagaa catccagcca ttctctgcca aagacctgtc cattogetca ctggggggacc 12120
gaatccggga tcttgctcag ctcaaaaatc totatccaa gaagcccaag gatgaggctt 12180
tccggagcca ctacaagcgt gagctggaac tggcagctct gattccttcc tgtcacccac 12240
ttcctccctg ctcctcgctg cctcctctc cctgcccgtg tgtcatcctg atgtcactcc 12300
ctatttcata gctgtgcttc tcttacttcc ccatgatcca tgcccacott ttccacctcc 12360
cttctccct aacccagag cactccatgg ctgtcttttc cttctcaca cagctgaaca 12420
gatgggtaag gatggcagg gttatgtccc agctaccatc aagatgaccg tggaaagggtg 12480

agtgtggtgg tatggacagt gggtaggtca ggggcttagt gcttatctgc aggaaggagg 12540
gggtggcatca acccttggtc agtcacatgt acctccttcc ctctccagg gaccaaccac 12600
ttcctacccc agagctccag atgcctacca tgggtgccttc ttatgacctt ggaatggccc 12660
ctgattcctc catgagcatg cagcttggcc cagatatggt gtaaggagct ggaaagacag 12720
gaatgggagt ggtctgtgca gatgggctaa tcttagcatg ggcagctggg agagctggca 12780
ctgggggctg aacagggaat cttcctttcc atgagaggga cacctgttca aaagcagggt 12840
gtggtggtgt ccaggagaag ggctggcatc aggggggtctg ttttctttcc ccaggcccca 12900
gggtgtacca ccacactctc actccatccc cccttatcaa ggcctctccc cagaagaatc 12960
agtcaacgtg ttgtcagcct tccaggagta agtgaaaaac ctcatgggga taccatccca 13020
ctctaagggg gtgggcattt gaattgttag aagaggctct tctgtgagaa aggagcagca 13080
aatgctaaca gcctgtcttc ttctctttctg tccactctaa tgagggggta gtagttaaga 13140
tctggactgc ctaggtttga attctagctc caccacttac tggtttgggg caaattactt 13200
agcctttggt gccttatctg cacaatgggg gataataatg ctaataataa taacctacct 13260
cactgcatta ttgtggagat taaatgagtt cataacactt aaaaagctga gcatagtgc 13320
tggctcatag caaaagctgt gtaagtccag tctgtgatca cttaatgaag gagcattttc 13380
tgtctttggc agtttcataa ttatgcgaat accattgagt ataattacac aaacctagat 13440
ggatatagact actatacact gaggtatat tgtgtagcct attgatccta gctttaaacc 13500
cgagcagcat gatactgttc tgaatagtat aaggaaatag taacataatg gtaaataattt 13560
gtgtgatagg aattttcagc ttgattataa tttttttttt ttgagacagg gtctcactca 13620
ctggagtgc gtggtgcgat cttagctccc tgcaacctcc gcctcttggg ctcgagcaat 13680
cctcctgctg tagtgcacca cgacactcgg ctaattcttt ttttaagattt ttctgcagac 13740
aagggtctcac ttactgcccc agctgggtctc aaactcctgg gcttaagtga tcctcccacc 13800
tcggcctccc aaagcgttag gattacagggc gtgagtcact ctgcctggcc ttgattataa 13860
tcttatggga ccaactgtggt ctgtagttga cagaaatgtc gttaatgtgg tgcagtactg 13920
ttattattat tttctgtcct gccoctgaga gccactgtca cttctctgct gtattggttt 13980
ttgtttactc atctgttttg gccttgaaat ggcttagaca ttttcttcc cgaagtatga 14040
cactcgggtg cttattaact tagtcaagac acaacatctc ccttcccaga aggtgaggcg 14100
ggagtgagga cttgggggact taagaactac caaagttcag agtccaaaga aacattagaa 14160

attggctaatt ccacccccat aacacgcaca ttttacagat gagaagactg agctcagagc 14220
atagaaatag cttgcccagg ccatgactaa gtcaggataa ggagctggag cttgtttcct 14280
cactcagtgg tcctgacttt gcaccactot gcatttgcoct agcctgcctt cctctaactg 14340
tgctctccct acttccaggc ctcacctgca gatgcccccc agcctggggc agatgagcct 14400
gccctttgac cagcctcacc ccagtgagt gacaaagccc ctctgaccc catgtgcctc 14460
ttctttcctg gccttgcccc gctctcotta ttccattgc tggttcctgg caggggcctg 14520
ctgccgtgcc agcctcagga gcatgctgtg tccagccctg acccctgct ctgctcagat 14580
gtgacctagg tggaagacag ctgcctgagc cagccagtga cagcgtttcc tcagggcact 14640
tggtagagtgg cagcttggga gtggaggctg ggtggcatct aggggagtgg gcgccatgcc 14700
tactccactg cttctcccat ctccctgcag gattggtgaa gacatattcc ctctctgct 14760
gcctccact gaacaggacc tactaagct tctcctggag gggcaagggg agtcgggggg 14820
agggtccttg ggggcacagc cctcctgca gccctccac tatgggcaat ctgggatctc 14880
aatgtccac atggacctaa gggccaaccc cagttggtga tccagctgg agggagaacc 14940
caaagagaca gctcttctac tacccccaca gacctgctt ggacacttgc tcatgccctg 15000
ccaagcagca gatggggagg gtgccctcct atccccacct actcctgggt caggaggaaa 15060
agactaacag gagaatgcac agtgggtgga gccaatccac tccttccttt ctatcattcc 15120
cctgcccacc tccttcagc actgactgga agggaagttc aggtctgag acacgcccc 15180
acatgcctgc acctgcagcg cgcacacgca cgcacacaca catacagagc tctctgaggg 15240
tgatggggct gagcaggagg ggggctgggt aagagcacag gtagggcat ggaaggcttc 15300
tcgcccatt ctgaccagg gcctaggacg gataggcagg aacatacaga cacatttaca 15360
ctagaggcca gggatagagg atattgggtc tcagccctag gggaatgga agcagctcaa 15420
gggaccctgg gtgggagcat aggaggggtc tggacatgtg gttactagta caggttttgc 15480
cctgattaaa aaatctccca aagccccaaa ttctgttag ccagggtggag gcttctgata 15540
cgtgtatgag actatgcaaa agtacaaggg ctgagattct tcgtgtatag ctgtgtgaac 15600
gtgtatgtac ctaggatatg ttaaataat agctggcacc ttagttgcat gaccacatag 15660
aacatgtgtc tatctgcttt tgctacgtg acaacacaaa tttgggaggg tgagacactg 15720
cacagaagac agcagcaagt gtgctggcct ctctgacata tgctaacccc caaatactct 15780
gaatttgagg tctgactgtg cccaagtggg tccaagtggc tgtgacatct acgtatggct 15840
ccacacctcc aatgctgct gggagccagg gtgagagtct ggggccaggc ctggccatgt 15900

ggccctccag tgtatgagag ggccctgcct gctgcatctt ttctgttgcc ccattccaccg 15960
 ccagcttccc ttcaactcccc tatcccatto tccctotcaa ggcaggggtc atagatccta 16020
 agccataaaa taaattttat tccaaaataa caaaataaat aatctactgt acacaatctg 16080
 aaaagaaaga cgctctaact gctcagatag gtgctgcggt ccagccccc gctggaggag 16140
 accctgagtc caaccaggc ctcccgagg ggccagtga gggatccac acccaccgcc 16200
 cctatgtagg gcagggaaga aattgcaaag gacttggggg atagatggga atgggagggc 16260
 aaactgcagc acttggttaa ttaattaaag aaacaaacca gaagcacaaa aacggggaag 16320
 gagaggggag aaggagcagg tccagtgttc ccaggccccc aattctgggg gcaaagtgtg 16380
 ccacttttag ctggaccttc ccagggaagt ccccttttcc cccttgtcca aactgagtcc 16440
 aactgctcac accactggtg caaacctaaa gagaatggga gtgtgttgtg tgaggaggag 16500

<210> 13

<211> 697

<212> DNA

<213> H. sapiens

<220>

<400> 13

ttctcttccc ttcaacttcc acactttgtc cctcccccca aattttttat ttttttgtcc 60
 acgccccaac aatttttttt gttttttttt tttaaaagaa tccacccctt ttctgagct 120
 ccctgactgg gatttcaactt cttcacctcc caccgtggcc accagagtta aaaacctatc 180
 ttataatata aaataaaaaa ggaaagaaag aaagaaaga aacctgtcc tcacctctt 240
 caggccctgg tctctgcccc tgggtggtoat cgtccatggc aaccaagaca acatgccaaa 300
 ccactatcct gtgggacatg ccttctctga gatggaccgc gtgocctttg tgggtggctga 360
 gcgggtgccc tgggagaaga tgtgtgaaac totgaacctg aagttcatgg ctgagggtggg 420
 gaccaaccgg gggctgctcc cagagcactt cctcttctg gccagaaga tcttcaatga 480
 caacagcctc agtatggagg ccttccagca ccgttctgtg tcctggctgc agttcaacaa 540
 ggagatcctg ctggccgtgg cttcaccttt tggcagtggg ttgatgggtg cctggacctc 600
 accaacgctg tctccggagc tactgggtctg accggtgagt cccaccctg ggtagtctga 660
 gcagccatac accagtcacc tccataactca ctgcccc 697

<210> 14

<211> 423

<212> DNA

<213> H. sapiens

<220>

<221> unsure

<222> 58

<223> unknown

<400> 14

tggacagtgg gtaggtcagg ggcttagtgc ttatctgcag gaaggagggg tggcatcnac	60
ccttggtcag tcacatgtac ctcttccct cctccaggga ccaaccactt cctaccccag	120
agctccagat gcctaccatg gtgccttctt atgaccttgg aatggcccct gattcctcca	180
tgagcatgca gcttggccca gatatggtgc ccaggtgta ccaccacac tctcactcca	240
tcccccgta tcaaggcctc tcccagaag aatcagtcaa cgtgttgta gccttccagg	300
agcctcacct gcagatgcc cccagcctgg gccagatgag cctgcccttt gaccagcctc	360
accccaggg cctgctgtcg tgccagcctc tggagcatgc tgtgtccagc cctgaccccc	420
tgc	423

<210> 15

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 15

agtgagcgaa tggacaggtc	20
-----------------------	----

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 16

cgctgtcact ggctggctca	20
-----------------------	----

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 17

ttgatgattt ctccagtgc	20
----------------------	----

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 18
aggacttcac ccagccggcc 20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 19
cccaggaacc tcaagcccaa 20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 20
gtcaccacaga agatgccgca 20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 21
tttccacggt catcttgatg 20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 22
aagatggtgc tcccctcccc 20

<210> 23
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 23
gccgtttcca aatctggatc 20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 24
ctttggctgc ctctagctct 20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 25
gtttggtgag gtccaggaca 20

<210> 26
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 26
catctgcagg tgaggctcct 20

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 27
tgcccttag gtccatgtgg 20

<210> 28
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 28
ctatctgtgg agagccatcc 20

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 29
attgagaaga aggctagtaa 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 30
gctgatgtgt tgcaagatgg 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 31
gccccatcac cctcagagag 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 32
ccctctgata tatgctctca 20

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33

gaaggctagt aacgtactgt

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34

gttccgtcgg gctcattgag

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35

gtcactggct ggctcaggca

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36

ttcagagttt cacacatctt

20

<210> 37

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 37

caggcccat aggtctgtag

20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38
tatcaagctg tgcagagaca 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 39
caggaactcc cagggctggc 20

<210> 40
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 40
gctctgtatg tgtgtgtgcg 20

<210> 41
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 41
agatcccgga ttcggtcccc 20

<210> 42
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 42
cgggtgcgcca ttccctgcca 20

<210> 43
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 43
gggatagaga tttttgagct 20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 44
gatctgggac ttggaggttg 20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 45
tccaaggtca taagaaggca 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 46
atgatcagcc ggtcagacca 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 47
cccaggaatg ctgttctcca 20

<210> 48
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 48
tctcaggact tcatccagcc 20

<210> 49

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 49
ccagcaggat ctccttggtg 20

<210> 50
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 50
tccagtgcctt tctgctccag 20

<210> 51
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 51
acagtgtctg aaagtagggc 20

<210> 52
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 52
gctggccctg ctagcacctc 20

<210> 53
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 53
ccacagagac atgatctggg 20

<210> 54
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54

gtcttaaact tgagttcttc

20

<210> 55

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55

tctagctctc cagtggcttc

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56

ggccctgacc agcggaggct

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57

cctctgtgac agactcagtg

20

<210> 58

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58

tccataactga ggctgttgtc

20

<210> 59

<211> 20

<212> DNA

<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 59
cctggccccg gatgacatgg 20

<210> 60
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 60
gaaggcacca tggtaggcat 20

<210> 61
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 61
ccaatccaag tgccctgagg 20

<210> 62
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 62
cagctgggat caccaactgg 20

<210> 63
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 63
gtgtctcaga gcctgaactt 20

<210> 64
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 64
taagcagtgg ctgccccagc 20

<210> 65
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 65
cctccctctt cagtgttaagc 20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 66
agaagccttc catgccctaa 20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 67
tatgttcctg cctatccgtc 20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 68
caactaaggt gccagctata 20

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 69

tggatcatgca actaaggtgc 20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 70
atttgtgttg tcacgtaggc 20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 71
tctcaccctc ccaaatttgt 20

<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 72
agcacacttg ctgctgtctt 20

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 73
gccaggcctg gaccagact 20

<210> 74
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 74
gggcaacaga aaagatgcag 20

<210> 75
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 75
aatgtcagct tttaatctgt 20

<210> 76
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 76
gagtcaatgc ctgagatggg 20

<210> 77
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 77
caggaagcaa ctgggagtga 20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 78
ccatctcaga gaaggcattg 20

<210> 79
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 79
tgcacatgtc cctgtgggat 20

<210> 80
<211> 20

<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 80
gggactcacc ggtcagacca 20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 81
agtgggttggc ccctggagga 20

<210> 82
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 82
agctccttac accatatctg 20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 83
caaagtgtgg aagtgaaagg 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 84
ctctggtggc cacggtggga 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 85
ggtgtatggc tgctcagact 20

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Antisense Oligonucleotide

<400> 86
aggaggtaca tgtgactgac 20

<210> 87
<211> 20
<212> DNA
<213> Homo sapiens

<400> 87
gacctgtcca ttcgctcact 20

<210> 88
<211> 20
<212> DNA
<213> Homo sapiens

<400> 88
tgagccagcc agtgacagcg 20

<210> 89
<211> 20
<212> DNA
<213> Homo sapiens

<400> 89
agcactggag aaatcatcaa 20

<210> 90
<211> 20
<212> DNA
<213> Homo sapiens

<400> 90
ttgggcttga ggttcctggg 20

<210> 91
<211> 20
<212> DNA
<213> Homo sapiens

<400> 91
gatccagatt tggaaacggc 20

<210> 92
<211> 20
<212> DNA
<213> Homo sapiens

<400> 92
agagctagag gcagccaaag 20

<210> 93
<211> 20
<212> DNA
<213> Homo sapiens

<400> 93
tgtcctggac ctcaccaaac 20

<210> 94
<211> 20
<212> DNA
<213> Homo sapiens

<400> 94
aggagcctca cctgcagatg 20

<210> 95
<211> 20
<212> DNA
<213> Homo sapiens

<400> 95
ccacatggac ctaagggccca 20

<210> 96
<211> 20
<212> DNA
<213> Homo sapiens

<400> 96
ggatggctct ccacagatag 20

<210> 97
<211> 20
<212> DNA
<213> Homo sapiens

<400> 97
ttactagcct tcttctcaat 20

<210> 98
<211> 20
<212> DNA
<213> Homo sapiens

<400> 98
ccatcttgca acacatcagc 20

<210> 99
<211> 20
<212> DNA
<213> Homo sapiens

<400> 99
ctctctgagg gtgatggggc 20

<210> 100
<211> 20
<212> DNA
<213> Homo sapiens

<400> 100
tgagagcata tatcagaggg 20

<210> 101
<211> 20
<212> DNA
<213> Homo sapiens

<400> 101
acagtacgtt actagccttc 20

<210> 102
<211> 20
<212> DNA
<213> Homo sapiens

<400> 102
ctcaatgagc ccgacggaac 20

<210> 103
<211> 20
<212> DNA
<213> Homo sapiens

<400> 103
tgcctgagcc agccagtgac 20

<210> 104
<211> 20
<212> DNA
<213> Homo sapiens

<400> 104
aagatgtgtg aaactctgaa 20

<210> 105
<211> 20
<212> DNA
<213> Homo sapiens

<400> 105
ctacagacct atggggcctg 20

<210> 106

<211> 20
<212> DNA
<213> Homo sapiens

<400> 106
tgtctctgca cagcttgata 20

<210> 107
<211> 20
<212> DNA
<213> Homo sapiens

<400> 107
gccagccctg ggagttcctg 20

<210> 108
<211> 20
<212> DNA
<213> Homo sapiens

<400> 108
cgcacacaca catacagagc 20

<210> 109
<211> 20
<212> DNA
<213> Homo sapiens

<400> 109
ggggaccgaa tccgggatct 20

<210> 110
<211> 20
<212> DNA
<213> Homo sapiens

<400> 110
tggcagggaa tggcgcaccg 20

<210> 111
<211> 20
<212> DNA
<213> Homo sapiens

<400> 111
caacctccaa gtcccagatc 20

<210> 112
<211> 20
<212> DNA
<213> Homo sapiens

<400> 112
tgccttctta tgaccttgga 20

<210> 113
<211> 20

<212> DNA
<213> Homo sapiens

<400> 113
tggtctgacc ggctgatcat 20

<210> 114
<211> 20
<212> DNA
<213> Homo sapiens

<400> 114
tggagaacag cattcctggg 20

<210> 115
<211> 20
<212> DNA
<213> Homo sapiens

<400> 115
caacaaggag atcctgctgg 20

<210> 116
<211> 20
<212> DNA
<213> Homo sapiens

<400> 116
ctggagcaga aagcactgga 20

<210> 117
<211> 20
<212> DNA
<213> Homo sapiens

<400> 117
gaggtgctag cagggccagc 20

<210> 118
<211> 20
<212> DNA
<213> Homo sapiens

<400> 118
cccagatcat gtctctgtgg 20

<210> 119
<211> 20
<212> DNA
<213> Homo sapiens

<400> 119
gagaccactg gagagctaga 20

<210> 120
<211> 20
<212> DNA

<213> Homo sapiens

<400> 120

agcctccgct ggtcagggcc

20

<210> 121

<211> 20

<212> DNA

<213> Homo sapiens

<400> 121

cactgagtct gtcacagagg

20

<210> 122

<211> 20

<212> DNA

<213> Homo sapiens

<400> 122

cctcagggca cttggattgg

20

<210> 123

<211> 20

<212> DNA

<213> Homo sapiens

<400> 123

aagttcaggc tctgagacac

20

<210> 124

<211> 20

<212> DNA

<213> Homo sapiens

<400> 124

gcttacactg aagagggagg

20

<210> 125

<211> 20

<212> DNA

<213> Homo sapiens

<400> 125

ttagggcatg gaaggcttct

20

<210> 126

<211> 20

<212> DNA

<213> Homo sapiens

<400> 126

gacggatagg caggaacata

20

<210> 127

<211> 20

<212> DNA

<213> Homo sapiens

<400> 127 tatagctggc accttagttg	20
<210> 128	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 128 gcaccttagt tgcacgacca	20
<210> 129	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 129 gcctacgtga caacacaaat	20
<210> 130	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 130 aagacagcag caagtgtgct	20
<210> 131	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 131 agtctgggtc caggcctggc	20
<210> 132	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 132 acagattaata agctgacatt	20
<210> 133	
<211> 20	
<212> DNA	
<213> Homo sapiens	
<400> 133 caatgccttc tctgagatgg	20
<210> 134	
<211> 20	
<212> DNA	
<213> Homo sapiens	

<400> 134
atccacagg gacatgtgca 20

<210> 135
<211> 20
<212> DNA
<213> Homo sapiens

<400> 135
tcctccagg accaaccact 20

<210> 136
<211> 20
<212> DNA
<213> Homo sapiens

<400> 136
agtctgagca gccatacacc 20

<210> 137
<211> 3790
<212> DNA
<213> Homo sapiens

<220>

<400> 137
gctgagaaag ggagaagaca gcagaggggt tgccgagaga aaggcctatt ggaggaacct 60
gagcaggagg ggtaaggatt ctgccttgag gagaaaagag ctggggcaac ctccaagtcc 120
cagatcatgt ctctgtgggg tctggtctcc aagatgcccc cagaaaaagt gcagcggctc 180
tatgtcgact ttccccaaca cctgcggcat cttctgggtg actggctgga gagccagccc 240
tgggagttcc tggctcggtc cgacgccttc tgctgcaact tggctagtgc cctactttca 300
gacactgtcc agcaccttca ggccctcgggtg ggagagcagg gggaggggag caccatcttg 360
caacacatca gcacccttga gagcatatat cagagggacc ccctgaagct ggtggccact 420
ttcagacaaa tacttcaagg agagaaaaaa gctgttatgg aacagttccg ccacttgcca 480
atgcctttcc actggaagca ggaagaactc aagtttaaga caggcttgcg gaggctgcag 540
caccgagtag gggagatcca ccttctccga gaagccctgc agaagggggc tgaggctggc 600
caagtgtctc tgcacagctt gatagaaact cctgctaata ggactgggcc aagtgaggcc 660
ctggccatgc tactgcagga gaccactgga gagctagagg cagccaaagc cctagtgtctg 720
aagaggatcc agatttgga aaggcagcag cagctggcag ggaatggcgc accgtttgag 780
gagagcctgg cccactcca ggagaggtgt gaaagcctgg tggacattta ttcccagcta 840
cagcaggagg taggggcggc tgggtggggag cttgagccca agaccgggc atcgtgact 900
ggccggctgg atgaagtcc gagaacctc gtcaccagtt gcttcctggt ggagaagcag 960
cccccccagg tactgaagac tcagaccaag ttccaggctg gagttcgatt cctgttgggc 1020
ttgaggttcc tggggggccc agccaagcct ccgctgggtc gggccgacat ggtgacagag 1080
aagcaggcgc gggagctgag tgtgcctcag ggtcctgggg ctggagcaga aagcactgga 1140
gaaatcatca acaacactgt gcccttggag aacagcattc ctgggaactg ctgctctgcc 1200
ctgttcaaga acctgcttct caagaagatc aagcgggtgt agcgggaagg cactgagtct 1260
gtcacagagg agaagtgcgc tgtgctcttc tctgccagct tcacacttgg ccccgcaaaa 1320
ctccccatcc agctccaggc cctgtctctg cccctgggtg tcatcgtcca tggcaaccaa 1380
gacaacaatg ccaaagccac tatcctgtgg gacaatgcct tctctgagat ggaccgcgtg 1440
ccctttgtgg tggctgagcg ggtgccctgg gagaagatgt gtgaaactct gaacctgaag 1500
ttcatggctg aggtggggac caaccggggg ctgctcccag agcacttccct cttcctggcc 1560
cagaagatct tcaatgacaa cagcctcagt atggaggcct tccagcaccg ttctgtgtcc 1620
tggtgcagtg tcaacaagga gatcctgctg ggcctgggtc tcaccttttg gcagtgggtt 1680
gatggtgtcc tggacctcac caaacgctgt ctccggagct actggtctga ccgcgactca 1740
gagattgggg gcatcaccat tgcccatgtc atccggggcc aggatggctc tccacagata 1800

```

gagaacatcc agccattctc tgccaaagac ctgtccatto gctcactggg ggaccgaatc 1860
cgggatcttg ctcagctcaa aaatctctat cccaagaagc ccaaggatga ggctttccgg 1920
agccactaca agcctgaaca gatgggtaag gatggcaggg gttatgtccc agctaccatc 1980
aagatgaccg tggaaaaggga ccaaccactt cctaccccag agctccagat gcctaccatg 2040
gtgccttctt atgaccttg gaaatggccct gattcctcca tgagcatgca gcttggccca 2100
gatatgggtg cccaggtgta cccaccacac tctcactcca tcccccgta tcaaggcctc 2160
tccccagaag aatcagtcaa cgtgttgta gccttcaggg agcctcacct gcagatgcc 2220
cccagcctgg gccagatgag cctgcccttt gaccagcctc acccccaggg cctgctgccg 2280
tgccagcctc agggagcatgc tgtgtccagc cctgaccccc tgctctgctc agatgtgacc 2340
atggtggaag acagctgcct gagccagcca gtgacagcgt ttctcaggg cacttggatt 2400
ggtgaagaca tattccctcc tctgctgcct cccactgaac aggacctcac taagcttctc 2460
ctggaggggc aaggggagtc ggggggaggg tccttggggg cacagccct cctgcagccc 2520
tcccactatg ggcaatctgg gatctcaatg tcccacatgg acctaggggc caacccagct 2580
tggtgatccc agctggaggg agaaccctaaa gagacagctc ttctactacc cccacagacc 2640
tgctctggac acttgcctcat gccctgccaa gcagcagatg gggaggggtgc cctcctatcc 2700
ccacctactc ctgggtcagg aggaaaagac taacaggaga atgcacagtg ggtggagcca 2760
atccactcct tcttttctat cattcccctg cccacctcct tccagcactg actggaaggg 2820
aagttcaggc tctgagacac gcccacacat gcctgcacct gcagcgcgca cacgcacgca 2880
cacacacata cagagctctc tgagggtgat ggggctgagc aggagggggg ctgggtaaga 2940
gcacaggtta gggcatggaa ggcttctccg cccattctga cccagggcct aggacggata 3000
ggcaggaaca tacagacaca tttaactag aggccaggga tagaggatat tgggtctcag 3060
ccctagggga atgggaagca gctcaaggga ccctgggtgg gagcatagga ggagtctgga 3120
catgtgggta ctagtacagg ttttgccctg attaaaaaat ctcccaaagc cccaaattcc 3180
tgtagccag gtggaggctt ctgatacgtg tatgagacta tgcaaaagta caagggtctga 3240
gattcttctg gtatagctgt gtgaacgtgt atgtacctag gatattgtta atatatagct 3300
ggcaccttag ttgcatgacc acatagaaca tgtgtctatc tgcttttgcc tacgtgacaa 3360
cacaaatttg ggagggtag acactgcaca gaagacagca gcaagtgtgc tggcctctct 3420
gacatatgct aacccccaaa tactctgaat ttggagtctg actgtgccc aagtggtcca 3480
agtggctgtg acatctacgt atggctccac acctccaatg ctgcctggga gccaggggtga 3540
gagtctgggt ccaggcctgg ccatgtggcc ctccagtgtg tgagagggcc ctgcctgctg 3600
catcttttct gttgccccat ccaccgccag ctcccttca ctccctatc ccattctccc 3660
tctcaaggga ggggtcatag atcctaagcc ataaaaataa ttttattcca aaataacaaa 3720
ataaataatc tactgtacac aatctgaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3780
aaaaaaaaaa 3790

```

<210> 138

<211> 3667

<212> DNA

<213> Homo sapiens

<220>

<400> 138

```

gacagagcta cagacctatg gggcctggaa gtgcccgtct agaaaggagg aagacagcag 60
aggggttgcc gaggaacct ccaagtccca gatcatgtct ctgtgggggtc tgggtctcaa 120
gatgccccca gaaaaagtgc agcggtctta tgtcgacttt ccccaacacc tgcggcatct 180
tctgggtgac tggctggaga gccagccctg agcatatata agagggagccc cctgaagctg 240
gtggccactt tcagacaaat acttcaagga gagaaaaaag ctgttatgga acagttccgc 300
cacttgccaa tgcttttcca ctggaagcag gaagaactca agtttaagac aggcttgagg 360
aggctgcagc accgagtagg ggagatccac cttctccgag aagccctgca gaagggggct 420
gaggctggcc aagtgtctct gcacagcttg atagaaactc ctgctaattg gactgggcca 480
agtgaggccc tggccatgct actgcaggag accactggag agctagaggc agccaaagcc 540
ctagtgtgta agaggatcca gatttggaag cggcagcagc agctggcagg gaatggcgca 600
ccgtttgagg agagcctggc cccactccag gagaggtgtg aaagcctggg ggacatttat 660
tcccagctac agcaggaggt aggggcggct ggtggggagc ttgagcccaa gaccgggcca 720
tcgctgactg gccggctgga tgaagtcctg agaaccctcg taccagtttg cttcctggtg 780
gagaagcagc cccccagggt actgaagact cagaccaagt tccaggctgg agtttcgattc 840

```

```

ctgttgggct  tgaggttcct  gggggcccca  gccaaagcctc  cgctgggtcag  ggccgacatg  900
gtgacagaga  agcagggcgcg  ggagctgagt  gtgcctcagg  gtccctggggc  tggagcagaa  960
agcactggag  aaatcatcaa  caacactgtg  cccttggaga  acagcattcc  tgggaactgc  1020
tgctctgccc  tgttcaagaa  cctgcttctc  aagaagatca  agcgggtgtga  gcggaagggc  1080
actgagtctg  tcacagagga  gaagtgcgct  gtgctcttct  ctgccagctt  cacacttggc  1140
cccggcaaac  tccccatcca  gctccaggcc  ctgtctctgc  ccctgggtggt  catcgtccat  1200
ggcaaccaag  acaacaatgc  caaagccact  atcctgtggg  acaatgcctt  ctctgagatg  1260
gaccgcgtgc  cctttgtggt  ggctgagcgg  gtgcccctggg  agaagatgtg  tgaaactctg  1320
aacctgaagt  tcatggctga  ggtggggacc  aaccgggggc  tgctcccaga  gcacttcctc  1380
ttcctggccc  agaagatctt  caatgacaac  agcctcagta  tggaggcctt  ccagcaccgt  1440
tctgtgtcct  ggtcgcagtt  caacaaggag  atcctgctgg  gccgtggctt  caccttttgg  1500
cagtggtttg  atggtgtcct  ggacctcacc  aaacgctgtc  tccggagcta  ctggtctgac  1560
cggctgatca  ttggcttcat  cagcaaacag  tacgttacta  gccttcttct  caatgagccc  1620
gacggaacct  ttctcctccg  ctctcagcag  tcagagattg  ggggcatcac  cattgcccac  1680
gtcatccggg  gccaggatgg  ctctccaacg  atagagaaca  tccagccatt  ctctgccaaa  1740
gacctgtcca  ttgctcact  gggggaccga  atccgggac  ttgctcagct  caaaaatctc  1800
tatcccaaga  agcccaagga  tgaggctttc  cggagccact  acaagcctga  acagatgggt  1860
aaggatggca  ggggttatgt  cccagctacc  atcaagatga  ccgtggaaag  ggaccaacca  1920
cttcttacc  cagagctcca  gatgcctacc  atggtgcctt  cttatgacct  tggaatggcc  1980
cctgattcct  ccatgagcat  gcagcttggc  ccagatatgg  tgcccaggt  gtaccacca  2040
cactctcact  ccatccccc  gtatcaaggc  ctctccccag  aagaatcagt  caacgtgttg  2100
tcagccttcc  aggagcctca  cctgcagatg  cccccagcc  tgggccagat  gagcctgccc  2160
tttgaccagc  ctacccccc  gggcctgctg  ccgtgccagc  ctccaggagca  tgctgtgtcc  2220
agccctgacc  ccctgctctg  ctccagatgtg  accatgggtg  aagacagctg  cctgagccag  2280
ccagtgcag  cgtttctca  gggcacttgg  attggtgaag  acatattccc  tcctctgctg  2340
cctccactg  aacaggacct  cactaagctt  ctctggagg  ggcaagggga  gtogggggga  2400
gggtccttgg  gggcacagcc  cctcctgcag  ccctcccact  atgggcaatc  tgggatctca  2460
atgtcccaca  tggacctaa  ggccaacccc  agttggtgat  ccagctgga  gggagaaacc  2520
aaagagacag  ctcttctact  acccccacag  acctgctctg  gacacttgct  catgccctgc  2580
caagcagcag  atggggaggg  tgccctccta  tccccacct  ctccctgggtc  aggaggaaaa  2640
gactaacagg  agaatgcaca  gtgggtggag  ccaatccact  ccttcccttc  tatcattccc  2700
ctgcccacct  ccttcagca  ctgactggaa  gggaggttca  ggctctgaga  cagcccccac  2760
catgcctgca  cctgcagcgc  gcacacgac  gcacacacac  atacagagct  ctctgagggt  2820
gatggggctg  agcaggaggg  gggctgggt  agagcacagg  ttagggcatg  gaaggcttct  2880
ccgcccattc  tgaccaggg  cctaggacgg  ataggcagga  acatacagac  acatttacac  2940
tagaggccag  ggatagagga  tattgggtct  cagccctagg  ggaatggga  gcagctcaag  3000
ggaccctggg  tgggagcata  ggaggagtct  ggacatgtgg  ttactagtac  aggttttgcc  3060
ctgattaaaa  aatctcccaa  agcccaaat  tcctgttagc  caggtggagg  cttctgatac  3120
gtgtatgaga  ctatgcaaaa  gtacaagggc  tgagattctt  cgtgtatagc  tgtgtgaacg  3180
tgtatgtacc  taggatatgt  taaatatata  gctggcacct  tagttgcatg  accacataga  3240
acatgtgtct  atctgctttt  gcctacgtga  caacacaaat  ttgggagggg  gagacactgc  3300
acagaagaca  gcagcaagtg  tgctggcctc  tctgacatat  gctaaccccc  aaatactctg  3360
aatttgaggt  ctgactgtgc  ccaagtgggt  ccaagtggct  gtgacatcta  cgtatggctc  3420
cacacctcca  atgctgcctg  ggagccagg  tgagagtctg  ggtccaggcc  tggccatgtg  3480
gccctccagt  gtatgagagg  gccctgcctg  ctgcattctt  totgttgccc  catccacgcg  3540
cagcttccct  tcactccct  atcccattct  ccctctcaag  gcaggggtca  tagatoccaa  3600
gccataaaat  aaattttatt  ccaaaataaa  aaaaaaaaaa  aaaaaaaaaa  aaaaaaaaaa  3660
aaaaaaa  3667

```

<210> 139

<211> 19

<212> DNA

<213> H. sapiens

<220>

<400> 139

cgagaggcgg acgggaccg

19

<210> 140

<211> 21

<212> DNA

<213> H. sapiens

<220>

<400> 140 .

cgagaggcgg acgggaccgt t

21

<210> 141

<211> 21

<212> DNA

<213> H. sapiens

<220>

<400> 141

cgggcccgtc cgcctctcgt t

21